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Acute pancreatitis is a condition characterized by acute inflammation of the pancreas.  In 
many instances the inflammation involves the peripancreatic soft tissue also. In majority of 
cases the inflammation is precipitated by pancreatic injury caused by either alcohol or gall 
stones1. However many other precipitating factors have been described to cause acute 
pancreatitis.  In about 10% of cases of acute pancreatitis no aetiology can be found1. The key 
initial event in the pathophysiology of pancreatitis is premature activation of pancreatic 
enzymes2. The mechanism that triggers this initial enzyme activation is still unknown. Once 
activated, trypsin leads to the enzymatic activation of other pancreatic enzymes like 
phospholipase A2, kallikrein and elastase. This premature activation can lead to autodigestion 
of the pancreatic tissue. The activated lipase can lead to peripancreatic fat necrosis. The 
circulating enzymes can also lead to systemic effects like increased capillary permeability, 
vasodilation and disseminated intravascular coagulation. Phospholipase A2 is known to have 
potent cytolytic effects.  This enzyme can degrade pulmonary surfactant and is thought to be 
one of the major mechanisms of pulmonary injury in acute pancreatitis3. The activated trypsin 
activates complements and kinins. These factors probably play a part in disseminated 
intravascular coagulation, renal failure and shock4. 
 
A variety of cytokines are activated by pancreatic inflammation. These cytokines play a 
major role in mediating the systemic inflammatory response syndrome and organ failure in 
acute pancreatitis5.  TNF alpha is one of the major cytokines that is released in response to 
early pancreatic injury. 
 
However in about 80% of the patients with acute pancreatitis the disease remains mild 
without any major local or systemic complications. The remaining 20% of the patients 
develop severe pancreatitis with local and systemic complications 6. In mild acute pancreatitis 
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the mortality is less than 1%. However in severe acute pancreatitis, mortality can reach upto 
25%7. Fifty percent of the deaths due to severe acute pancreatitis occur within the first two 
weeks of illness 8. Systemic inflammatory response syndrome and organ failure accounts for 
majority of these deaths. Infective complications mainly infected pancreatic necrosis and 
sepsis accounts for most of the cases with late mortality. Even though there are various 
prognostic scores which can predict severe pancreatitis, it is still unknown why some patients 
develop mild pancreatitis and others develop severe disease. TNF alpha polymorphisms have 
been shown to affect the severity of pancreatitis through a modifier effect i.e. ,they do not per 
se cause pancreatitis but once pancreatitis sets in, those with these polymorphisms develop a 
more severe disease compared to those without9. The G→A transition at position 308 in the 
promoter region of TNF alpha gene is one of the most commonly studied polymorphisms9. 
However the results of such studies have been conflicting.  
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AIMS AND OBJECTIVES 
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1. To study the clinical profile and in- hospital outcomes  of patients presenting with 
acute pancreatitis 
2. To determine whether there is any association between TNF alpha gene 
polymorphisms [TNF 308 G/A(rs1800629), TNF 857 C/T (rs1799724) ,TNF 863 C/A 
(rs1800630)]with the  severity of illness and hospital outcomes in patients with  acute 
pancreatitis. 
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Acute pancreatitis- mortality and incidence 
 
One of the earliest descriptions of acute pancreatitis was given by Reginald Fitz (1889) 
defines it as a condition characterized by pancreatic haemorrhage, gangrene and disseminated 
fat necrosis11. Most episodes of this disease are mild and self-limiting. About 20% of the 
patients develop severe attacks with both local and systemic complications12. The overall 
mortality of acute pancreatitis is about 5-10% which can go up to 35% or higher if 
complications develop13. In spite of the advances in medicine and critical care, the mortality 
due to pancreatitis has not come down significantly14.The incidence of acute pancreatitis is 
known to differ in different geographical regions due to the differences in alcohol 
consumption or in incidence of gallstones disease15,16. The incidence of acute pancreatitis has 
increased during the past few years in many countries17 .This rise is probably secondary to 
increasing alcohol consumption and a rising prevalence of obesity and gallstone disease. 
 
Pathophysiology  
The exocrine pancreas secretes about 1500 - 2000 ml of fluid and 150 - 200 mmol of HCO3
- 
daily in response to secretin, and secretes amylolytic, lipolytic and proteolytic digestive 
enzymes in response to cholecystokinin or muscarinic cholinergic stimulation18.Enzymes for 
proteolysis are secreted in an inactive precursor form. These have to be activated to their 
active forms by trypsin. Trypsinogen, the precursor of trypsin is converted to its active form 
with the help of enterokinase,an enzyme secreted from the mucosa of 
duodenum.Otherproteolytic enzymes like chymotrypsinogen, proelastase, 
procarboxypeptidases and lipolytic and amylolytic enzymes are converted to their active form 
with the help of trypsin. These enzyme precursors are stored in the zymogen granules. There 
are various antitrypsins( inhibitors of trypsin) like pancreatic secretory trypsin inhibitor,α1-
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antitrypsin and α2-macroglobulin. The above mentioned mechanisms protect the pancreas 
from enzymatic digestion. When these mechanisms fail, there will be premature activation of 
pancreatic proenzymes thereby leading to pancreatic parenchymal damage. 
The initial abnormality causing the activation of precursor enzymes has been postulated to be 
a persistent increase in cytosolic calcium within the pancreatic acinar cell which leads to 
intracellular activation of the digestive enzymes19. 
Various mechanisms have been proposed to explain why the natural defences against 
unbridled pancreatic enzyme activation fail.  
1. Pancreatic duct hypertension-An  increase in the pancreatic ductal pressure resulting from 
outflow obstruction by any cause like a stone, oedema or sphincter spasm might rupture the 
small pancreatic ducts and cause extravasation of pancreatic juice into the gland20. 
2. Duodenopancreatic reflux- Reflux of duodenal contents through the papilla leads to the 
activation of trypsinogen to trypsin by the intestinal enterokinase21. The reflux can occur 
through a papilla that has been made incompetent by inflammation caused by various 
mechanisms (eg: alcohol, passed out stone, endoscopic cannulation or surgery). The activated 
trypsin leads to activation of phospholipase A2. Phospholopase A2 acts on lecithin (which is a 
normal constituent of the bile) and forms lysolecithin. Lysolecithin damages pancreatic cell 
membranes leading to progressive tissue damage and edema of the pancreatic ducts 22. 
3. Reduced apical exocytosis of pancreatic zymogens- It has been proposed that in acute 
pancreatitis, there is increased intracellular accumulation of zymogen granules, consequent to 
a decreased in apical secretion and a normal rate of production. With increased accumulation, 
some of these granules eventually fuse with lysosomal membranes. Within the lysosomes, the 
enzyme cathepsin B activates trypsinogen to trypsin. The activated trypsin activates other 
zymogens causing progressive tissue damage 23. 
4. Hypersecretion- In rare situations like organophosphorous poisoning, the disease may be 
caused by an excess secretion of enzymes due to excess muscarinic stimulation 24. 
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The non-infectious destruction of the pancreatic tissue by the above mechanisms leads to an 
inflammatory reaction at the site of injury (which is the normal response of human body to 
any injury). However what makes pancreatitis different is its propensity to amplify this 
localized process into a systemic inflammatory response syndrome (SIRS)25which inturn is 
responsible for its morbidity and mortality26. Acinar injury leads to expression of endothelial 
adhesion molecules(e.g., VCAM-1) which leads to recruitment of leucocytes and propagation 
of the inflammatory response27. In early stages of pancreatitis, it has been found that the 
activation of complement system and the subsequent release of C5a play significant roles in 
the recruitment of macrophages and polymorphonuclear leukocytes28.Active granulocytes 
and macrophages release proinflammatory cytokines. The major proinflammatory cytokines 
include TNF alpha, IL-1, IL-6, IL-8, and platelet-activating factor (PAF).Proinflammatory 
cytokine release is usually followed by the release of anti-inflammatory cytokines (IL-2, IL-
10, IL-11) that attempts to down-regulate inflammation29. 
 
SIRS is common in patients with acute pancreatitis and is probably mediated by activated 
pancreatic enzymes (phospholipase, elastase, trypsin) and cytokines (TNF, PAF) which are 
released into the portal circulation from the inflamed pancreas30.Thesecytokines reach the 
liver and activate the hepatic Kupffer cells, which in turn induces hepatic expression and 
secretion of cytokines into the systemic circulation. This cytokine storm amplifies SIRS and 
in some cases leads to multiorgan dysfunction and death31. The circulating pancreatic 
enzymes can also lead to systemic effects like increased capillary permeability, vasodilatation 
and disseminated intravascular coagulation. The vasodilatation and increased capillary 
permeability secondary to the inflammatory mediators lead to many of the systemic 
complications like hypotension, third space fluid loss and acute renal failure. Myocardial 
depression secondary to vasoactive peptides might also contribute to hypotension. The 
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activated trypsin also activates complements and kinins. These factors are postulated to play a 
part in disseminated intravascular coagulation, renal failure and shock 4. ARDS could be 
induced by active phospholipase A2 (lecithinase) which digests lecithin,a major component 
of lung surfactant. 
 
Local complications- The initial tissue injury and inflammation leads to increased 
expression of endothelial adhesion molecules. This leads to enhanced recruitment of 
leucocytes and macrophages to the site of injury. These cells in turn produce further 
proinflammatory cytokines and enhance inflammation. Increased vascular permeability 
secondary to inflammation leads to edema of the gland- interstitial/edematous pancreatitis. 
Experimental models have shown that microcirculatory changes including vasoconstriction, 
capillary stasis, decreased oxygen saturation and progressive ischemia occur in acute 
pancreatitis. Mediators of inflammation like arachidonic acid metabolites (prostaglandins, 
PAF, leucotrienes), nitric oxide and reactive oxygen species interact with pancreatic 
microcirculation to increase vascular permeability, induce thrombosis and haemorrhage 
thereby causing pancreatic necrosis. In some patients, ischemia and severe inflammation of 
the gland can lead to disruption of the main and secondary pancreatic ducts leading to local 
fluid accumulations within and surrounding the pancreas that can later develop into 
pseudocysts32.Pancreatic fistulas are also caused by disruption of the pancreatic duct and 
should be suspected in patients who develop massive ascites or pleural effusions33.Infection 
of the necrotic pancreatic tissue or pseudocyst leading to an infected pancreatic necrosis or an 
infected pseudocyst can occur from the blood stream or from translocation of bacteria from 
the gut into the lymphatics. Under normal circumstances, translocation of gut bacteria does 
not occur because of the complex immunologic and morphologic barriers present. However, 
during acute pancreatitis, these barriers are down resulting in local and systemic 
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infection34.The likely explanations for the penetration of the gut barrier by enteric bacteria are 
gut ischemia secondary to hypovolemia and pancreatitis-induced arteriovenous shunting in 
the gut35. 
 
Cytokines 
Cytokines are a group of low molecular weight proteins (usually 16 to 25 kDa) that are 
produced within numerous cell types as a means of cell to cell communication36. Each 
cytokine has the ability to act on many different target cells rather than a single cell type.  
This property is termed pleiotropism. Cytokines also exhibit redundancy. This means that 
different cytokines can induce an identical biologic effect. Once a cytokine is produced, it has 
the ability to stimulate enhanced production of itself as well as many other cytokines, 
resulting in amplification of the inflammatory process and the development ofcascades25. 
Cytokines are usually active in very small (femtomolar) concentrations and their productionis 
tightly regulated37. Barring a few exceptions, cytokines are not constitutively produced. 
Instead, the cell of origin is activated to produce new cytokine mRNA during times of stress 
or in response to an external stimulus. In most instances, the tissue levels of cytokines are 
more important for the biological effects than the blood levels 25. 
 
Cytokines in acute pancreatitis 
Many authors have reported that the circulating levels of various cytokines (IL-6, IL-8, TNF 
alpha) are higher in patients with complicated and severe pancreatitis when compared to mild 
cases 37,38. IL-1 and TNF are the primary members of the inflammatory cytokine family. 
They are primary inducers of IL-6 and IL-8 production.  All  of the serious  consequences of 
severe sepsis such as fever, circulatory collapse, cardiac dysfunction , metabolic acidosis,  
and the production of ARDS are known to be initiated by TNF alpha and IL-140. Almost all  
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experimental models of pancreatitis have implicated IL-1and TNF as the major pathologic 
cytokines associated with local and systemic tissue complications 25.  Studies on circulating 
human monocytes and polymorphonuclear leucocytes have shown that TNF, IL-6 and 1L-8 
production was higher in patients with acute pancreatitis.  Another important observation was 
that leucocytes from patients with complicated pancreatitis were hyperstimulated when 
compared to those from patients with mild pancreatitis 41,42. 
 
During early hours of acute pancreatitis, pancreatic parenchyma produces 1L-1, TNF and   
IL-6 43. However the predominant source of cytokines in acute pancreatitis is the invading 
leucocytes. An important observation made from experimental models of acute pancreatitis 
was that the concentration of TNF and IL-1 within pancreatic tissues was substantially higher 
than the serum levels, levels that are known to be toxic to many cell types44. Grewal 
et al have  shown that levels of TNF alpha  in the portal vein of animals with pancreatitis was  
significantly higher than corresponding systemiclevels45. They postulated that the liver was 
serving to clear TNF thereby preventing it from reaching the general circulation. The 
expression of TNF receptors was also found to be increased during acute pancreatitis.de 
Beaux and colleagues have shown that the serum levels of TNF receptors predicted organ 
failure during AP even when TNF itself was not detectable46. IL-1 and TNF are both 
produced systemically during pancreatitis in addition to local production47. Some studies 
have shown that the production of IL-1 and TNF in the pulmonary parenchyma could be 
directly linked to ARDS in sepsis and acute pancreatitis 48. Almost all animal studies have 
conclusively proved that these cytokines alone cannot initiate pancreatitis. Perfusion of the 
isolated human pancreas with high doses of IL-1 and TNF have shown little evidence that 
these agents can initiate an attack of acute pancreatitis49. However studies on gene knockout 
animals have proven beyond doubt that these agents play a role in determining the severity of 
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acute pancreatitis. When acute pancreatitis is induced in animals devoid of IL-1 or TNF 
receptors, they fail to develop maximal pancreatitis50.Pancreatitis does develop in these 
transgenic animals, yet its severity/lethality never reaches that of wild-type mice. These 
studies thereby establish that although pancreatitis is not initiated or triggered by 1L-1 or 
TNF, they both play an important role in its progression. 
 
Several investigators have demonstrated that acute pancreatitis is associated with the 
induction of acinar cell apoptosis, the degree of which might determine the severity of 
pancreatitis51.When pancreatic acinar cells in vitro are exposed to high concentrations of TNF 
as found in pancreatic tissues during pancreatitis, a large portion becomes apoptotic51. 
Various animal studies have shown that TNF blockade during acute pancreatitis would 
decrease pancreatic necrosis and inflammation and decrease mortality by about fifty 
percent52,53. 
TNF alpha gene polymorphisms -The gene that encodes for TNFα is located on the short 
arm of chromosome 6 within the major histocompatibility complex (MHC) class III54.Tumor 
necrosis factor production is regulated at the transcriptionallevel55.Evidence from 
experimental and clinical studies has suggested that increased secretion of tumour necrosis 
factor-α (TNF-α) and interleukin-1β (IL1-β) is important in mediating organ dysfunction in 
severe acute pancreatitis25,46.Genetic factors might influence levels of cytokine production56. 
Certain polymorphisms in the TNF alpha gene has been found to be associated with increased 
levels of TNF alpha production 57-59. Such genetically determined differences in levels of 
cytokines following an insult might explain individual differences in disease severity in a 
variety of inflammatory disorders such as acute pancreatitis. If disease severity can be shown 
to be positively predicted by these polymorphisms, they might serve as excellent prognostic 
markers for these diseases since the direct measurement of these cytokines in blood is often 
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erratic in view of the intermittent nature of secretion, low half life of cytokines in circulation 
and clearance by the liver42. Moreover in diseases like pancreatitis it might be the tissue 
levels of these cytokines that are more important than the blood levels. 
 
TNF alpha polymorphisms in diseases 
In a study from Taiwan, Lu et al. studied 424 dyspeptic patients with H.pylori infection. They 
studied TNF-alpha promoter SNP over the locus on -1031(T/C), -863(C/A), -857(C/T), -
806(C/T), and -308(G/A) by sequence-specific oligonucleotide probe60. They found that 
among the H. pylori-infected patients, those with -1031C or -863A allelles of TNF-alpha 
promoter had more severe gastric neutrophil infiltration and TNF-alpha gastric staining than 
individuals with -1031TT or -863CC genotype. They also found that -1031C and -863A 
carrier status were independent risk factors for developing duodenal and gastric ulcers in H. 
pylori-infected hosts.  
 
In study from Australia, O'Callaghanet al studied more than 600 patients with IBD61.They 
studied the TNF alpha promoter polymorphisms at positions -1031T/C, -863C/A, -857C/T, -
308G/A  by PCR-RFLP  method. They found that the TNF alpha -857C allele was strongly 
associated with the risk of IBD. Previous studies had already shown that the TNF alpha -
857C allele was associated with increased expression of TNF alpha in IBD 62. 
 
Studies have also shown that TNF alpha promoter region polymorphisms are associated with 
poor outcomes in patients with cerebral malaria and meningococcal disease 63,64.  
 
In a study of 106 critically ill patients, Surbatovicet al. have studied their outcomes and the 
relation to TNF-α308, IL-101082, CD14159, and IL-1ra gene intron2 genotype 
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polymorphisms 65. Nearly half of these patients had severe sepsis secondary to trauma. There 
were fifteen patients with acute pancreatitis. Distribution of 3 TNF-α308 genotypes (AA, AG, 
GG) was associated with primary outcome (death) with statistical significance. All the 
patients with AA genotype survived (7/7). Relative risk of death with AG genotype was 
3.250 and with GG genotype was 1.923. No significant association of the TNF genotype was 
found with the type of microorganism or the underlying cause of sepsis. 
 
 In a study from Taiwan, Chang et al. have studied TNF alpha polymorphisms in patients 
with chronic pancreatitis66. They studied 70 cases (48 men and 22 women) and 286 
control subjects (151 men and 135 women). They studied five TNF alpha promoter 
polymorphisms (-1031, -863, -857, -308, and -238) using direct sequencing.The-863A allele 
of the TNF-alpha promoter was found to be associated with an increased risk for chronic 
pancreatitis (odds ratio (OR) 4.949 (95%confidence interval (CI) 2.678–9.035). 
 
Chang et al have studied a group of 126 hypertriglyceridemia patients in Taiwan 67. 46 of 
these patients had history of pancreatitis (probably secondary to hypertriglyceridemia) and 80 
patients never had a pancreatitis episode. The authors tried to study why some people with 
hypertriglyceridemia developed pancreatitis while others did not. They studied TNF promoter 
polymorphisms (nucleotide positions 1031, 863, 857, 308, and 308) by direct sequencing. 
They also studied mutations in PRSS1, SPINK1 and CFTR genes. They found that TNF 
promoter 863A allele was an independent risk marker for pancreatitis in patients with 
hypertriglyceridemia. 
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TNF alpha polymorphisms in acute pancreatitis 
One of the earlier studies on the association of TNF alpha gene polymorphisms and the 
severity of acute pancreatitis was published in 200168. In this study, Powell et al studied 190 
patients with acute pancreatitis and 102 healthy volunteers. Of the 190 patients, 113 patients 
had mild disease and 77 patients had severe disease. Alcohol was the commonest aetiology in 
both the groups. They had used the 1992 Atlanta classification system to classify mild and 
severe disease. Mortality was 2% in the mild group and 22% in the severe group. 
 
TNF (TNF-308, TNFB), IL-1β, and IL-1 receptor antagonist (IL-1ra) genotypes were 
determined for both the patients and the control group. The TNF-308 polymorphism occurred 
with equal frequency in both cases and controls. Moreover there was no difference in the 
distribution of the mutant allele between the patients with mild and severe pancreatitis. 
Furthermore TNFB, IL-1β, and IL-1 receptor antagonist (IL-1ra) genotype polymorphisms 
also did not show any significant difference between mild and severe pancreatitis and also 
between cases and controls. 
 
In 2003 another study on TNF alpha gene polymorphisms and acute pancreatitis was 
published by Zhang et al. from China69. In this study they included only patients with biliary 
pancreatitis. A total of 127 patients and 102 healthy controls were studied. The diagnosis of 
acute pancreatitis was based on clinical criteria, an increased amylase and lipase activity 
(enzymatic colorimetric test) in serum and CT evidence of pancreatitis. Severe pancreatitis 
was diagnosed in those patients with an APACHE score of ≥ 8 or CT severity index of ≥ 4. 
They had used the ACCP/SCCM consensus criteria for the diagnosis of septic shock. The 
controls were healthy volunteers. They studied the TNF alpha -308 polymorphism in the 
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promoter region of TNF alpha gene and another polymorphism at position +252 in the first 
intron of TNF β. They also measured plasma TNF alpha levels in all patients with acute 
severe pancreatitis at admission. Of the 127 patients 61 patients had severe pancreatitis and 
the rest had mild disease. 18 patients had documented septic shock .The TNF-308 
polymorphism, TNF2 was found in18 (29.5 %) of patients with severe pancreatitis compared 
with 17 (25.8 %) of patients with mild pancreatitis. There was no significant difference. 
Further there was no significant difference in the distribution between cases and controls. A 
similar insignificant result was found for TNF β polymorphism also. Among the 61 patients 
with severe pancreatitis, TNF alpha levels at admission were similar in those patients who 
developed septic shock and those who did not. There was no significant correlation between 
the TNF alpha- 308 polymorphisms and plasma TNF alpha levels at admission in the patients 
studied. This study however found a significant difference in the TNF alpha- 308 
polymorphism distribution when comparing patients with and without septic shock. TNF2 
was found in 50 %of patients who developed septic shock compared with 20.1 % of  
patients with no septic shock (odds ratio- 5.155, P=0.023). 
 
In 2005 Balog et al. had published a study from Hungary 9. They had studied TNF-alpha, 
HSP70-2, and CD14polymorphisms in patients with acute pancreatitis and tried to correlate 
the polymorphisms with disease severity. It was a prospective single centre trial from a 
teaching hospital in Hungary. Acute pancreatitis was diagnosed based on the clinical 
history consistent with pancreatitis, radiologic evidence, and a serum amylase level greater 
than 660 U/L. They recruited a total of 77 patients with acute pancreatitis. 71 healthy controls 
were also included. Alcohol was the commonest aetiology in this series and in eight out of 77 
patients, no cause could be identified. They classified the disease as mild or severe based on 
the original Ranson’s criteria. Those patients with a score of less than three were classified as 
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mild and those with a score of ≥3 were classified as having severe pancreatitis. The diagnosis 
of infected pancreatic necrosis was made based on the cultures of pancreatic tissue obtained 
by either USG or CT guided procedures. Twenty nine of the 77 patients had mild disease and 
forty eight patients had severe disease based on their definition. Of the patients with severe 
pancreatitis 20 patients had infected pancreatic necrosis. In both cases and controls they 
studied the TNF alpha -308 polymorphism by PCR-RFLP method. There was no statistically 
significant difference in the distribution of the TNF alpha -308genotype between the patients 
and the healthy controls. However the GA genotype was more common in patients with 
severe pancreatitis compared to those with mild disease with an odds ratio of 3.145. The 
number of homozygotes for the inflammatory allele (AA genotype) was very low in this 
study (2 out of 77 patients) 
 
Tukiainen et al have studied TNF alpha, CD-14, HSPA1B genes in patients with acute 
pancreatitis.70. They studied 397 patients with acute pancreatitis and 300 healthy controls. Of 
the 397 patients, 214 had alcohol induced pancreatitis. It was a single centre study from 
Helsinki university hospital. The diagnosis of acute pancreatitis was based on the typical 
clinical signs of abdominal pain accompanied by plasma amylase level more than 3 times the 
normal upper limit, or a positive CT scan finding. They had excluded all patients with 
chronic pancreatitis and all patients with more than three episodes of acute pancreatitis in the 
past. The disease was classified as mild or severe based on the 1992 Atlanta criteria. Patients 
with organ failure requiring either mechanical ventilation or dialysis were classified as a 
separate subgroup of severe pancreatitis. Septic complications were defined as positive blood 
cultures or positive cultures from abdominal drains or operative samples. Of the 397 patients 
studied, 152 had severe pancreatitis. Of these 152 patients with severe pancreatitis, 55 
patients had severe pancreatitis with organ failure. Five patients had succumbed to the disease 
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during hospital stay. 74 patients had past history of acute pancreatitis. They studied the TNF 
promoter-308 G/A (rs1800629) polymorphism in this study. The distribution of the genotypes 
was in Hardy-Weinberg equilibrium for the TNF polymorphism. There was no significant 
difference in the TNF alpha genotype distribution between the mild and severe pancreatitis 
cases. The genotype distributions of the subgroup of patients with organ failure and the 
patients with mild acute pancreatitis were also comparable. There were 47 patients with 
septic complications. The distribution of TNF alpha polymorphisms were similar between 
this group and patients with mild acute pancreatitis without any infective complications. 
There was no significant difference in the TNF alpha genotype distribution between cases 
and healthy controls. Till 2008, this was the study on TNF alpha polymorphisms in acute 
pancreatitis with the largest sample size. 
 
In another study published in the same year (2008) de-Madaria et al. reported their 
experience with TNF-238 polymorphisms71. It was a single centre prospective study from 
Spain. Consecutive patients with acute pancreatitis were included. Exclusion criteria were 
age under 18 years, admission after 48 hours of the onset of the symptoms, any chronic 
inflammatory disease, concurrent infections, neoplastic diseases, chronic renal failure and 
chronic liver disease. In this study, all patients received prophylactic antibiotics (imipenem 
500 mg every eight hours).All the patients with SIRS, APACHE score ≥ 8, or CRP level >15 
mg/dl or any organ failure underwent a contrast enhanced CT abdomen at 72 hours after 
admission. The disease was classified as mild or severe based on the Atlanta 1992 criteria. 
All the local and systemic complications were also defined as per the Atlanta 1992 criteria. 
Mortality was defined as death during admission and any death after discharge secondary to a 
complication of pancreatitis. A blood sample was obtained within 72 hours after the onset of 
symptoms from all patients for cytokine levels and genetic polymorphisms. They had studied 
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the TNF alpha-308 and TNF alpha-238 polymorphisms by PCR RFLP method. A total of 84 
patients were studied. Sixty six percent of the patients had biliary pancreatitis. Twenty one 
patients (25%) had severe pancreatitis. Nine patients had organ failure and fifteen patients 
had local complications. Of the eighty four patients studied, two patients died due to 
multiorgan failure. 
The GA genotype of the TNFalpha -238 polymorphism was associated with more frequent 
organic failure than the GG genotype. The TNF alpha -308 polymorphism did not show any 
statistically significant correlation with the outcomes of acute pancreatitis. The observed 
frequency of single nucleotide polymorphisms were in accordance with the Hardy-Weinberg 
equilibrium.  Both the polymorphisms studied did not show any correlation with the cytokine 
levels in the patients studied. 
 
In 2010, Ozhan et al. published another study on the outcomes of pancreatitis and TNF gene 
polymorphisms. The study was from a teaching hospital in Turkey72. Two polymorphisms in 
the promoter region (positions −308 and −238) in TNFα gene were studied. They recruited 
103 patients with acute pancreatitis and 92 healthy controls .The criteria for diagnosis of AP 
were: a clinical history consistent with the pancreatitis, radiological evidence, and serum 
amylase level greater than 3 times the upper limit of normal. The patients were recruited at 
the time of admission. The progress of the patients during the hospital stay was followed up.  
The disease was classified as mild or severe based on Atlanta 1992 criteria. There were 68 
patients with mild pancreatitis and 35 patients with severe disease. The TNF alpha gene 
polymorphisms were studied by PCR-RFLP method. The observed frequency of all SNPs 
satisfied the Hardy-Weinberg equilibrium. Genotype distribution of two SNPs (rs1800629; 
rs361525)in cases and controls did not show any statistically significant difference. There 
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was no difference in the distribution of TNF alpha gene polymorphisms studied between 
patients with mild and severe disease. 
 
In one of the latest studies in this field published in 2012;Bishehsari et al evaluated 211 
patients with acute pancreatitis and 401 controls73. The main outcomes studied were 
persistent SIRS and MODS (multi organ dysfunction syndrome). Persistent SIRS was defined 
as SIRS lasting for more than 48 hours. MODS was defined as failure of ≥2 organ systems 
(cardiovascular, pulmonary, and/or renal) persisting more than 48 h. Subjects were analyzed 
for the SNPs at -1031 C/T (rs1799964), -863 A/C (rs1800630), -857 C/T (rs1799724), -308 
A/G (rs1800629), and -238 A/G (rs361525) in the TNF alpha gene. Twenty-three of 211 
AP patients (11%) developed MODS. The distribution of the TNF gene  polymorphisms were 
similar in the patients and the control group. However progression to MODS was associated 
with the minor allele at -1031C (56.5% vs. 32.4% P = 0.022, OR: 2.7; 95%CI: 1.12-6.51) and 
-863A (43.5% vs. 21.8% P = 0.022, OR: 2.76; 95%CI: 1.12-6.74). 
 
Every single study published till date has proven beyond doubt that TNF alpha promoter 
polymorphisms do not increase the susceptibility to acute pancreatitis. The distribution of 
polymorphisms in every study is similar in both cases and controls. However the data on the 
effect of these polymorphisms on the outcome of pancreatitis is variable. There are some 
studies which have shown that these polymorphisms have a modifier effect on the outcome of 
pancreatitis whereas other studies have shown that these polymorphisms have no effect on 
the outcome of acute pancreatitis9,68-73. The sample size in most of these studies was arbitrary. 
A sample size calculation based on the prevalence of the polymorphisms of interest in the 
population studied was not done in most of the studies.  
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Study design  
This was a cross sectional study performed in the Christian Medical College, Vellore. 
 
Inclusion criteria  
Patients who presented to CMC Vellore with acute pancreatitis or complications of acute 
pancreatitis and who gave an informed consent to be part of our study were included in the 
study.  
Diagnosis of acute pancreatitis was based on the following criteria 
1. Pain characteristic of pancreatitis 
2. Elevated serum amylase and lipase levels (>3 times upper limit of normal) 
3. Imaging suggestive of pancreatitis 
If any two of the above criteria were present, a diagnosis of acute pancreatitis was made 
 
 
Study duration 
 
September 2012 to December 2013. 
 
 
Exclusion criteria 
Patients with evidence of underlying chronic pancreatitis (ductal dilatation, ductal or  
parenchymal calcification). 
Patient (or legally accepted representative) not willing to be part of the study. 
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Study setting and Population 
The study was conducted in the department of Gastrointestinal Sciences in CMC Hospital, 
Vellore from September 2012– December 2013. 
 
 
Methods 
 Patients were recruited to the study from either the emergency medical services or wards by 
the primary investigator after getting an informed consent. A detailed history and clinical 
examination was done at the time of recruitment. The blood sample for genetic analysis was 
taken at the time of recruitment. The clinical course of the patient was followed up by the  
primary investigator. The investigations and treatment decisions for the patient was decided 
by the treating unit .No additional clinical laboratory investigations were performed for the 
study other than those essential for clinical care. Consecutive patients were enrolled, subject 
to consenting. The genetic testing was performed in a research laboratory attached to the 
department by a specialist. The clinical investigator was blinded to the genetic data, while the 
molecular biologist was blinded to the clinical data. Any patient with either local or systemic 
complication was classified as having severe pancreatitis. Those patients without a local or 
systemic complication were classified as having mild pancreatitis. Atlanta 2012 classification 
was used to define local and systemic complications 10. 
 
Sample size  
From unpublished data from our department (on-going community based studies), we found 
that the inflammatory TNF alpha (TNF 308 G/A) genotype is present in approximately eight 
percent  of our population and the TNF 863 AA genotype is 7.6%.The hypothesis was that 
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this single nucleotide polymorphism (or other SNPs in the same gene) may have a ‘modifier’ 
effect on the course of acute pancreatitis. Therefore we expect that eight percent of patients 
with acute pancreatitis would also have this inflammatory genotype. 
Sample size calculation was done using the following assumptions: 
 In hospitalized cases with acute pancreatitis, we expect the cases of acute severe pancreatitis 
(ASP) to constitute 33% and acute mild pancreatitis (AMP) to constitute 67%. In control 
population we know that the frequency of the two major SNPs each is 8% or 0.08 of the 
population. To detect a significant association between ASP and the SNP with an Odds Ratio 
of 4, with a type I error of 0.05 and power of 0.80, we will need to study a total of 168 
patients with acute pancreatitis. 
 
Ethics Committee review  
The Human Ethics Committee of CMC Vellore reviewed and approved the proposal and 
consent forms. 
 
Genetic analysis 
9 ml of venous blood samples were collected in EDTA coated tubes after obtaining informed 
written consent.  DNA was isolated using standard salting out procedure. Genomic DNA 
from mononuclear cells in blood was extracted by salting out and stored at −20°C . All the 
three polymorphisms (rs1800629, rs1799724,rs1800630) were studied by PCR-RFLP 
methods. The PCR reactions were of 20 µlvolume and each reaction mix contained 1x taq 
DNA polymerase master mix Red (Ampliqon), and 250nM of forward and reverse primers 
(Shrimper).  
The thermal cycling protocol for rs1800629, rs2227956, rs1799724, and rs1800630comprised 
of initial denaturation at 95°C for 5 min, cycle denaturation at 94°C for 30 sec, annealing 
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temperature at 57°C for rs1800629, 55°C for rs1799724 and 56°C for rs1800630 a extension 
at 72°C for 30 sec, and the cycle was repeated for 34 more times, final extension at 72°C for 
5 min. The PCR products were checked for amplification by resolving on 2% agarose gel 
electrophoresis and checked with UV transilluminator  (VilbertLourmat).  
The amplified samples were digested with restriction enzymes- NcoI two units overnight 
incubation at 37°C for rs1800629(-308G/A), Tai I four units overnight incubation at 65°C for 
rs 1799724(-857C/T) and rs1800630(-863C/A).The digested PCR products were resolved on 
2% agarose gel electrophoresis and the gel patterns were documented using a gel 
documentation system (VilbertLourmat, France).  
 
The genotypes were assigned for the PCR-RFLP analysis as given in the table. 
 
SNP Forward primer Reverse primer 
Product 
size 
Restrictio
n enzyme 
Restriction 
fragments 
rs1800629
TNF 308G/A) 
5-AGGCAATAGGTTTTGAGGGCCAT-3 
5-TCCTCCCTGCTCCGA 
TTCCG-3 
I07 bp 
Nco I 
2 units 
G-87 &20 
A-107 
rs1799724 
(TNF 857C/T) 
5-GGCTCTGAGGAATGGGTTAC-3 
5-CCTCTACATGGCCC 
TGTCTAC-3 
128 bp 
Tai I 
4 units 
 C-110&18 
T-128 
Rs1800630 
TNF 863C/A 
5-GGCTCTGAGGAATGGGTTAC-3 
5-CTACATGGCCCTG 
TCTTCGTTACG-3 
125 bp 
Tai I 
4 units 
C-125 
A-104&21 
 
Statistical methods: 
The data of the present study were recorded manually and into the computer and after its 
proper validation, checked for error, coding & decoding were compiled and analyzed using 
the software SPSS 11.5 for Windows. Categorical data was compared using the Pearson Chi 
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square test, while continuous data was compared using two-tailed independent t tests. All the 
continuous variables were expressed as mean ± standard deviation. 
The Atlanta 2012 classification had included a new group called moderately severe 
pancreatitis for those patients with only local complications or systemic complications which 
last for less than 48 hours. For the purpose of analysis, the moderately severe group was also 
classified as severe pancreatitis. Those patients who were discharged against medical advice 
in a moribund condition were also classified as dead for the purpose of analysis. 
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RESULTS 
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A total of 179 patients were recruited as part of this study between September 2012 and 
December 2013. Eleven of these patients were excluded due to underlying chronic 
pancreatitis on imaging. The remaining 168 patients who gave informed consent to be part of 
the study were included. Of these 168 patients, 164 were admitted to the wards and four 
patients were discharged from the emergency medical services. 151 patients presented 
directly to our centre with an acute episode of pancreatitis, whereas seventeen patients were 
initially managed elsewhere and thereafter presented to our centre with complications of 
acute pancreatitis. 
 
 
Fig 1- Age and sex distribution of  the study population 
 
82% of the study population were males (138/168). Majority of the patients (76.7%) were in 
the age group of 18-55 years. 19% of the study population was >55 years and 4% of the 
patients were less than 18 years of age. The mean age of the study population was 40.55± 
15.02 years. Sixty two (36.9%) patients had a comorbid medical illness. Hypertension was 
the commonest medical illness in the study population. Few patients had multiple 
comorbidities. 
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Figure 2- Comorbidities in the study population 
 
 
Clinical Presentation 
The patients with acute pancreatitis had presented to hospital after a median duration of three 
days after the onset of pain. All the patients had abdominal pain at the onset of symptoms. 
98.8% of the patients had vomiting associated with pain. Thirty four patients (20.2%) had 
breathlessness at presentation. Three patients gave history of decreased urine output at 
presentation. Sixteen patients (9.5%) had documented fever at presentation. Twenty patients 
(11.9%) had hypotension at presentation. Table 1 shows the baseline parameters of the study 
population at presentation. 
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Table 1 - Baseline parameters of the study population at presentation 
Particulars Total 
Total cases 168 
Age(years) 40.55 ± 15.02 
Male:Female 4.6 :1 
SGS score 1.96 ± 1.55 
CRP(mg/L) 110.37 ± 77.25 
Amylase (U/L) 944.55 ± 938.79 
Lipase(U/L) 1867.97± 2448.03 
PCV (%) 41.52 ± 7.86 
Abbreviations: 
SGS – Simplified Glasgow score, CRP – C reactive protein, PCV – Packed cell volume 
 
The mean age of the study population was 40.55±15.02 years. The Simplified Glasgow Score 
(SGS) at admission ranged from a minimum value of 0 to a maximum value of six, the 
median being two. SGS>2 was present in 66 patients at admission. The mean duration of 
hospital stay for the study population was 10.05±8.76 days. All patients underwent a chest X 
ray and ultrasound scan of the abdomen. A CT scan was done only in those patients where it 
was thought to be necessary by the treating physician. Eighty three patients out of the 168 
underwent a CT scan at some point during the hospital stay. 
Sixty eight patients (40.4%) had an abnormal chest x ray at presentation. Twenty seven 
(16.07%) patients had a left sided pleural effusion. Thirty five (20.8%) patients had bilateral 
effusion at presentation. An ARDS-like picture was present in six patients. Hundred patients 
had a normal chest X ray. 
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Figure 3- Simplified Glasgow Score and Chest X ray on presentation 
 
 
The initial screening ultrasound scan showed a bulky/edematous pancreas in 149 (88.69%) of 
patients. An acute fluid collection was present at admission in 54 (32.14%) of patients. 
 
Complications 
During the course of hospital stay seventy two patients (42.85%) had one local complication 
of pancreatitis or other. Acute fluid collection was the commonest local complication which 
was present in 54 (32.1%) of the patients. Pancreatic necrosis and related complications like 
necrotic collection, walled off pancreatic necrosis were present in thirty three patients 
(19.6%).  
An infected pancreatic necrosis was diagnosed based on the presence of air in the pancreatic 
parenchyma (indicating the presence of gas forming organisms) in a patient who had not 
undergone any interventional procedure or had a positive culture in a diagnostic aspirate from 
the pancreatic necrosis. A diagnostic aspirate was done only in those cases where the 
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clinician suspected an infected necrosis. In our study population an infected pancreatic 
necrosis was proven based on imaging or culture in six patients. 
 
Twenty four (14.28%) patients had some vascular complication secondary to acute 
pancreatitis. Twenty three (13.69%) patients had splenic vein thrombosis. Nineteen( 11.3%)  
patients had isolated  splenic vein thrombosis. Two patients had splenic vein thrombosis and   
superior mesenteric venous thrombosis. Two patients had splenic vein thrombosis extending 
to the portal vein. One patient developed a jejunal artery pseudoaneurysm. This patient 
developed massive GI bleed during the hospital stay which settled following a coil 
embolization of the pseudoaneurysm.  
 
As already discussed seventeen of our patients were treated elsewhere for acute pancreatitis 
and presented to our centre later on with some complication or the other. Of these seventeen 
patients, thirteen patients had presented with a pseudocyst of pancreas. 
 
Pancreatic ascites is a local complication of severe acute pancreatitis caused by pancreatic 
duct disruption secondary to severe inflammation in acute pancreatitis. This condition is 
characterized by a high ascitic fluid amylase, lipase values and demonstration of duct 
disruption on imaging. Six of our patients developed pancreatic ascites during the course of 
hospital stay. 
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Figure 4- The spectrum of local complications in the study population 
 
 
Sixty eight (40.47%) patients had a systemic complication of pancreatitis documented during 
hospital stay. In twenty three patients, the systemic complication was transient (lasting less 
than 48 hours), whereas in forty five patients the systemic complication was persistent 
(lasting more than 48 hours). Acute lung injury was the commonest systemic complication. 
Sixty two (36.9%) patients had acute lung injury as a complication of acute pancreatitis. 
Thirteen (7.73%) patients had documented hypotension as a complication of acute 
pancreatitis. Twelve (7.14%) had acute kidney injury as defined by a serum creatinine 
concentration of more than 1.9 mg/dl . 
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Figure 5 - Spectrum of systemic complications in the study population 
 
 
Infectious complications 
During the course of hospital stay, eleven patients had proven bacteremia. E.coli was the 
commonest organism isolated. Six patients met the criteria for infected pancreatic necrosis 
(either a positive culture on diagnostic aspirate or imaging evidence). Figure 6 shows the 
spectrum of organisms identified on blood culture. Six patients had documented infected 
peripancreatic collections (diagnosed based on a positive culture from a diagnostic aspirate). 
Seven patients developed urinary tract infection during the hospital stay.  Four patients 
developed hospital acquired pneumonia. 
Table 2- The spectrum of infectious complications in the study population 
INFECTIOUS COMPLICATION NO: OF PATIENTS 
Bacteremia 11 
Infected pancreatic necrosis 6 
Infected fluid collection 6 
Urinary tract infection 7 
Hospital acquired pneumonia 4 
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Fig 6- Organisms isolated in patients with bacteremia 
 
 
Other complications 
Three patients in the study population had exacerbation of underlying COPD during hospital 
stay. One patient had an unstable angina while he was admitted for acute pancreaitis. Two 
patients had pulmonary embolism while they were admitted for treatment of acute 
pancreatitis. During hospital stay for acute pancreatitis, four patients had GI bleed. Two of 
these patients had gastric ulcer and one patient had a duodenal ulcer. The fourth patient with 
GI bleed was diagnosed to have a jejunal artery pseudoaneurysm. This patient underwent a 
coil embolization of the jejunal artery and bleed was controlled. All the patients with ulcer 
disease improved with conservative management. 
 
Etiology of acute pancreatitis 
Alcohol and gall stone disease accounted for the etiology in 64.8% of our patients. There 
were seventy nine patients with alcohol induced acute pancreatitis and thirty patients with 
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gall stone induced pancreatitis. In forty two(25%) patients the cause of pancreatitis was not 
evident after extensive evaluation. They were labelled as idiopathic pancreatitis.  
In five patients, hypercalcemia secondary to hyperparathyroidism was the etiology of acute 
pancreatitis. One of these patients with hyperparathyroidism came with a very severe attack 
of acute pancreatitis and died in the ICU. In all the other patients, parathyroid adenoma was 
diagnosed on further evaluation and they underwent surgery for the same. All these patients 
except one had come with the first episode of pancreatitis. None of them were known to have 
hyperparathyroidism prior to this attack of pancreatitis. Acute pancreatitis was the presenting 
symptom of hyperparathyroidism in these patients. 
There were six cases of probable drug induced acute pancreatitis. There was one patient with 
recurrent acute pancreatitis in whom pancreas divisum was diagnosed on evaluation. There 
were four patients in the study population who presented with acute pancreatitis after an 
ERCP procedure. There was one patient in whom the evaluation of acute pancreatitis led to 
the detection of an ampullary neoplasm. 
Table 3- Etiology of acute pancreatitis in the study population 
ETIOLOGY NO: OF PATIENTS(n=168) 
Alcohol 78(46.4%) 
Gall stones 30(17.8%) 
Idiopathic 42(25%) 
Hypercalcemia 5(2.9%) 
Drug induced 6(3.5%) 
Post ERCP 4(2.3%) 
Pancreas divisum 1 
Ampullary growth 1 
Hypertriglyceridemia 1 
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Table 4- Drugs implicated as etiology in the study population 
DRUG NO: OF CASES 
Anti retroviral therapy 2 
L- Asparaginase 2 
Prednisolone 1 
Lamivudine 1 
 
Patients with recurrent acute pancreatitis 
There were twenty nine patients in our series who presented with recurrent acute pancreatitis. 
The number of past attacks in these patients ranged from two to eleven. The mean age of this 
population was 32±13.17 years. Twenty six (89.7%) of the twenty nine patients were male. 
Alcohol (48.27%) was the commonest etiology in this group. Eighteen patients had mild 
disease. Only two patients had persistent organ failure. 
Table 5- Etiology of pancreatitis in patients with recurrent acute pancreatitis 
ETIOLOGY NO: OF CASES(n=29) 
Alcohol 14(48.2%) 
Idiopathic 11(37.9%) 
Gall stones 2(6.8%) 
Pancreas divisum 1(3.4%) 
Hyperparathyroidism 1(3.4%) 
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Table 6- Baseline characteristics of patients with recurrent acute pancreatitis(n=29) 
Particulars Value 
Age(years) 32.00± 13.17 
Male:Female 8.6:1 
SGS score(mean) 1±1.13 
CRP(mg/L) 87.35±80.68 
% of mild cases 62.06% 
Abbreviations: SGS- Simplified Glasgow Scoring, CRP- C reactive protein 
 
Severity of illness 
Based on the presence of local and systemic complications, the patients were categorized into 
mild, moderate and severe as per the Atlanta 2012 criteria. There were seventy three(44%) 
patients with mild disease, fifty one patients with moderate disease (30%) and forty four 
(26%) patients with severe disease. By our study definition any patient with either a local or 
systemic complication was classified as severe pancreatitis. So as part of our analysis we 
clubbed together the patients with moderately severe disease and severe disease into a single 
group as severe pancreatitis. 
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Figure 7- Severity of illness in the study population 
 
 
 
 
 
ICU stay and organ support 
During the course of hospital stay, seventeen patients(10.1%) required admission in the 
intensive care unit. The commonest reason for ICU admission was acute lung injury. Fifteen 
patients required mechanical ventilatory support. Of these, fourteen patients required invasive 
mechanical ventilation and one patient required noninvasive ventilation. Thirteeen patients 
required inotropic support. Three patients underwent hemodialysis during their stay in the 
ICU. The duration of hospital stay ranged from 1 to 46 days. The median duration of ICU 
stay was nine days. 
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Figure 8 - ICU admission and organ support in the study population 
 
 
 
Surgery and other interventions 
Surgical necrosectomy was done in one patient during the course of our study. Three patients  
underwent endoscopic necrosectomy. Endoscopic ultrasound guided pseudocyst drainage was 
done in four patients.  Eleven patients had ultrasound/CT guided drainage procedure for 
infected collections/ necrosis. One patient with a jejunal artery pseudoaneurysm, who 
presented with a massive GI bleed underwent interventional radiology guided coil 
embolization of the pseudoaneurysm. Nine patients underwent ERCP owing to associated 
cholangitis. 
In sixty two (36.9%) patients, a nasojejunal tube was placed for early enteral nutrition. Seven 
patients with severe disease expired during the initial days of admission while they were still 
on intravenous fluids. The rest of the patients were started on oral diet once their pain settled. 
None of the patients in our series were given total parenteral nutrition.  
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Figure 9- Interventions in the study population                                                                                                                
 
 
 
Figure 10- The mode of nutrition in the study patients 
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Mortality in the study population 
 
One hundred and sixty eight patients with acute pancreatitis were enrolled in our study. Ten 
patients (5.95%) expired during the hospital stay. Five patients  (2.97%) were discharged 
against medical advice in a very serious condition. One hundred and fifty three patients were 
discharged alive in a stable condition. Of the ten patients who died in hospital, eight of the 
died within eight days of admission secondary to complications of SIRS. The remaining two 
patients died after twenty three and thirty three days of admission respectively, secondary to 
infectious complications and sepsis. Four of the five patients who were discharged against 
medical advice left at least after two weeks of admission. One patient left against medical 
purpose on the eight day of admission. For the purpose of analysis, the patients who left 
against medical advice are also classified as dead owing to their moribund status. 
 
Figure 11- Primary outcome in the study population 
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Genetic analysis 
DNA extraction and genetic analysis were successful in all 168 patients. The allele 
frequencies for all the three major polymorphisms were determined. The results were in 
Hardy –Weinberg equilibrium except the TNF 308 polymorphism. The differences in the 
distribution of genotypes between mild and severe cases, patients with local complications 
and those  without, patients with systemic complications and those without, patients who 
required ICU stay and those who did not & patients who died due to the illness and those who 
survived were analyzed. 
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Figure 12- TNF-308G/A PCR 
 
 
 
 
Figure 13- TNF 308 G/A RFLP 
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Figure 14- TNF 857 C/T PCR 
 
 
 
 
TNF-857 C/T RFLP
Digestion Volume- 20µl, Tai 1 Enzyme- 4U, Assay Buffer-1X19-12-13
M    91   92    93   94     95    96   97    98    99   100  101 102  103  104  105  106  107  108  109  110   111  112  113 114  115      
-128bp
-110bp
Figure 15- TNF 857 C/T RFLP 
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TNF-863 C/A  PCR
20µl Reaction vol. – 35cycles.. Ann.Temp- 56°c, Ann time- 30s25-7-13
M        81       82        83        84        85       86        87        88        89       90                 
- 125bp
 
Figure 16 TNF -863 C/A PCR 
 
 
 
 
Figure 17- TNF 863 C/A RFLP 
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Table 7- TNF 308 polymorphisms and   outcomes 
COMPLICATION OUTCOME GA GG P VALUE 
Local 
complication 
Absent 4 92 0.72 
Present 4 68 
Systemic 
complication 
Absent 4 96 0.71 
Present 4 64 
Severity Mild 3 70 1.00 
Severe 5 90 
ICU stay No 8 143 1.00 
Yes 0 17 
Outcome Alive 8 145 1.00 
Dead 0 15 
 
 
 
Table 7 shows the distribution of TNF 308 genotypes. The AA genotype was absent in our 
study population. The distribution of genotypes was compared against various outcomes of 
pancreatitis like local complications, systemic complications, severity of illness, the need for 
ICU stay and mortality by Fischer exact test. The parameters studied did not show any 
statistically significant association with the inflammatory genotype GA. More over the 
distribution of TNF 308 genotypes did not satisfy the Hardy –Weinberg equilibrium. 
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Table 8- TNF-857 polymorphisms and outcomes 
COMPLICATION OUTCOME CC CT TT P VALUE 
Local 
complication 
Absent 83 11 2 0.01 
Present 50 21 1 
Systemic 
complication 
Absent 84 13 3 0.02 
Present 49 19 0 
Severity Mild 64 7 2 0.01 
Severe 69 25 1 
ICU stay No 121 27 3 0.45 
Yes 12 5 0 
Outcome Alive 122 28 3 0.64 
Dead 11 4 0 
 
 
 
 
 
Table 8 shows the distribution of TNF 857 genotypes.  The association of the CT and TT 
genotypes with the outcomes of pancreatitis like local comlications, systemic complications, 
severity of illness, the need for ICU stay and mortality was studied by Chi square test. Local 
complications, systemic complications, and severity of illness showed a statistically 
significant association with the CT and TT genotypes. However  mortality and the need for 
ICU admission did not show this association. 
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Table 9- TNF-863  polymorphisms and outcomes 
COMPLICATION OUTCOME AA CA CC P VALUE 
Local 
complications 
Absent 15 20 61 0.23 
Present 8 23 41 
Systemic 
complications 
Absent 14 21 65 0.24 
Present 9 22 37 
Severity Mild 12 14 47 0.21 
Severe 11 29 55 
ICU stay No 20 39 92 0.87 
Yes 3 4 10 
Outcome Alive 21 41 91 0.49 
Dead 2 2 11 
 
 
Table 9 shows the distribution of TNF 863 genotypes. The distribution was in Hardy –
Weinberg equilibrium. The association of the AA and CA genotypes with the outcomes of 
pancreatitis was assessed by Chi square test. The studied parameters did not show a 
statistically significant association with the inflammatory genotypes. 
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DISCUSSION 
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Study population 
Our study included all patients with acute pancreatitis. No age group was excluded from our 
study. Four percent of our patients were less than eighteen years of age and nineteen percent 
of the patients were more than fifty five years of age. Some studies in the past have excluded 
patients more than 75 years of age69. de-Madaria et al have excluded patients less than 
eighteen years of age in their study71.  
 
Ourcriteria for the diagnosis of acute pancreatitis was similar to almost all previous studies. 
Our study population consisted of a heterogenous group of patients with all etiologies of 
acute pancreatitis included for the study. Most of the studies in the past have also included all 
etiologies of acute pancreatitis. However, Zhang et al included only patients with biliary 
pancreatitis which was a more homogenous study population69. Moreover this study also 
included only those patients with first attack of acute pancreatitis. Our study included patients 
with recurrent attacks of acute pancreatitis provided they were not known to have underlying 
chronic pancreatitis. After inclusion, if a further imaging in hospital showed evidence of 
chronic pancreatitis, those patients were excluded. In our study eleven patients were excluded 
after initial inclusion since further imaging during the hospital stay showed evidence of 
chronic pancreatitis. Some investigators like Tukiainenet al have excluded those patients with 
more than three episodes of acute pancreatitis, due to the possibility of underlying chronic 
pancreatitis70. We have included patients with recurrent attacks even when the number of 
attacks were>5 times when there was no evidence of chronic pancreatitis. However in our 
patients, a CT scan was done only when the clinician suspected a complication of acute 
pancreatitis. An imaging at admission was not done in any of our patients, even in those with 
recurrent attacks, to ruleout chronic pancreatitis. So it is possible that few of our study 
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patients might have underlying chronic pancreatitis.Most of the other studies on TNF 
polymorphisms have also included patients with recurrent attacks. Zhang et al included only 
those patients who presented to hospital within 36 hours of the onset of pain69. de-Madariaet 
al have excluded those patients who presented after 48 hours of the onset of pain71. In both 
these studies serum levels of cytokines were also measured in addition to the genotype 
determination. Since our study did not involve cytokine measurements, we included patients 
with acute pancreatitis regardless of the time duration between the onset of pain and the 
presentation to hospital. 
 
The mean age of our study population was 40.55± 15.02 years. Our study population was 
about a decade younger than most other published studies.  The mean age in the study 
population of  Ozhan et al  was 52.7±15.1 years72. The median age of the patients in the study 
by Tukiainen et al was 51 years70. In the study by Powell et al, the median age of the patients 
with mild pancreatitis group was 51 years and the median age of the patients in the severe 
pancreatitis group was 57 years. 
 
 In our study, alcohol was the most common etiology accounting for 46.4 percent of the 
cases. Gallstones were the cause of acute pancreatitis in only 17.8 percent of our patients. The 
study by Zhang et al included patients with only biliary pancreatitis. In the studies by 
Tukiainenet al and  Baloget al, alcohol was the most common etiology of acute pancreatitis, 
accounting for 61 percent and 44.15 percent respectively70,9. However, in the studies by de-
Madaria et al and Powell et al, gall stones were the predominant cause of acute pancreatitis, 
accounting for 61 percent and 42.63 percent of the cases respectively71,68. A large proportion 
of our cases were idiopathic(25%). We have classified them as idiopathic after excluding all 
the known causes of acute pancreatitis. Other series have also reported idiopathic cases but in 
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relatively small numbers. In the study by Powell et al; out of the total 190 patients studied, 
thirty patients(15.7%) were classified as idiopathic. de-Madaria et al have reported that 18% 
of their patients with acute pancreatitis were idiopathic. Balog et al have reported that 10.3% 
of patients in their study had no known etiology of acute pancreatitis. These patients were 
classified as idiopathic. 
 
Complications and severity of illness 
In our study we have classified any patient with a local or systemic complication as having a 
severe disease. We used the Atlanta 2012 classification to define the local and systemic 
complications. Although the Atlanta 2012 classification has a group called moderately severe 
pancreatitis, we clubbed the moderately severe and severe pancreatitis groups together as 
severe pancreatitis. Different studies in the past have used different criteria to assess the 
severity of illness. Tukiainen et al 70,de-Madaria et al71 ,Ozhanet al 72,Powell et al68 have used 
Atlanta 1992 classification to define severe pancreatitis. The classification of mild and severe 
pancreatitis in these studies is similar to our study. Zhang DL et al 69 have classified their 
patients into severe pancreatitis based on an APACHE score of ≥8 and a CTSI ≥4.Balog A et 
al 9 have classified all patients with acute pancreatitis as mild and severe based on the original 
criteria of Ranson. Any patient with a Ranson score of more than or equal to three were 
classified as having severe pancreatitis. This was one major study that reported a positive 
correlation between TNF 308G/A polymorphism and severity of acute pancreatitis. However 
it can be seen that the classification into severe disease in this study was not based on the 
development of local or systemic complications but based on a score at admission. 
 
In our study, 57% of study population had severe disease while only 43% had a mild disease. 
This is contrary to the general expectation that two thirds of the patients with acute 
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pancreatitis have mild disease. This could be because of the fact that only those patients with 
severe disease could have been referred to our hospital, which is a tertiary referral centre. 
Other studies on acute pancreatitis have also reported similar results. Balog et al 9 reported 
that 62.3% of their patients with acute pancreatitis had severe disease. In the study by Zhang 
et al 69 severe   pancreatitis accounted for 48.03% of cases with acute pancreatitis. 
 
In our study 42.8%of the study population had one local complication or another. However it 
must be emphasized that a CT scan was done only in eighty three patients (49.4%) of the total 
study population since it was performed only when the treating physician suspected a local 
complication based on the clinical status of the patients. It might very well be possible that 
pancreatic necrosis and related complications could have been present in some patients who 
were relatively asymptomatic for whom a CT scan was not considered. We did not have a 
predefined set of criteria prior to ordering for CT. In the study by de-Madaria et al,71 a CT 
scan was ordered in those patients who met any of the following criteria: 
a. Presence of SIRS 
b. Presence of organ failure 
c. CRP >15 mg/dl 
d. APACHE score>8 
In that study fifteen out of eighty three patients had local complications of acute 
pancreatitis(18.07%). None of the studies on acute pancreatitis had CT scan done in all the 
patients. 
 
The mortality from acute pancreatitis in our study was about 9%. Powell et al68have reported 
22% mortality in severe pancreatitis and 2% mortality in mild pancreatitis in their study of 
190 patients. de-Madaria et al71 have reported two deaths in their study of eighty four patients 
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with acute pancreatitis. In the study by Tukiainen E et al70 , of the 397 patients studied there 
were five deaths. 
 
In our study eleven patients had proven bacteremia during the course of hospital stay. E.coli 
was the commonest organism isolated. Six patients met the criteria for infected pancreatic 
necrosis (either a positive culture on diagnostic aspirate or imaging evidence). Six patients 
had documented infected peripancreatic collections (diagnosed based on a positive culture 
from a diagnostic aspirate). Balog et al 9reported that twenty percent of their patients with 
acute pancreatitis had infected pancreatic necrosis. Tukiainen et al70 have reported that 
infectious complications developed in forty seven patients of a total of 397 patients studied. 
 
Genetic analysis  
Our study showed a significant association between TNF 857C/T polymorphisms and the 
severity of acute pancreatitis. Both the local and systemic complications of acute pancreatitis 
were significantly associated with this polymorphism. However the study did not show a 
statistically significant association of this polymorphism with the need for ICU stay or 
mortality in our population. This could probably be because of the fact that the number of 
patients in both these groups were low. Only seventeen patients in our study population 
required ICU stay and only fifteen patients died ( ten patients who expired in hospital and 
five patients who were discharged against medical advice). 
 
Ours was not the first study on the association between TNF 857C/T polymorphisms and the 
severity of acute pancreatitis. In 2012Bishehsari et al had studied 211 patients with acute 
pancreatitis and 401controls.73In this study there was no significant difference in the 
distribution of TNF 857 genotypes between the cases and controls. Moreover the study did 
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not show a significant association between TNF 857 C/T polymorphisms and the outcomes of 
acute pancreatitis. No other group has studied TNF 857 C/T polymorphisms in acute 
pancreatitis before this. Our study is the first to report a positive association between TNF 
857C/T polymorphisms and the outcomes of acute pancreatitis. 
Almost every study in the past while evaluating the association between the outcomes of 
acute pancreatitis and TNF polymorphisms had a control group. The aim of having this 
control group was to study if the TNF polymorphisms predispose the carriers of these mutant 
allelles to acute pancreatitis. However none of these past studies showed a difference in the 
distribution of TNF genotypes between the cases and controls. Our study did not have a 
control group. Our hypothesis was that TNF polymorphisms could have a modifier effect on 
acute pancreatitis, that is these polymorphisms as such do not cause acute pancreatitis, 
however if a patient developed acute pancreatitis, they affect the severity of acute 
pancreatitis. Our hypothesis was in accordance with data from animal studies which have 
conclusively shown that high cytokine levels alone cannot initiate acute pancreatitis. 
Perfusion of the isolated human pancreas with high doses of IL-1 and TNF have shown little 
evidence that these agents can initiate an attack of acute pancreatitis49. The modifier effect of 
TNF levels is further demonstrated by studies in gene knockout animals. When acute 
pancreatitis is induced in animals devoid of IL-1 or TNF receptors, they fail to develop 
maximal pancreatitis50.Pancreatitis does develop in these transgenic animals, yet its 
severity/lethality never reaches that of wild-type mice. These studies thereby establish that 
pancreatitis is not initiated or triggered by 1L-1 or TNF, however they both play an important 
role in its progression. So in our study the mild and severe groups of pancreatitis were 
compared against each other. 
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These polymorphisms studied are in the promoter region of the TNF alpha gene.  Past studies 
have proven that polymorphisms in the TNF alpha gene are associated with increased levels 
of TNF alpha production57,58,59. So it might be possible that such genetically determined 
differences in the level of this key cytokine might affect the progression of disease and 
outcome in acute pancreatitis once an acute insult has initiated the injury. This also might 
explain the individual differences in disease severity in patients suffering the same initial 
insult. 
 
TNF alpha levels 
If the disease severity in acute pancreatitis is modified by the levels of inflammatory 
cytokines, it appears logical that measuring blood levels of TNF alpha might serve as a 
prognostic marker in acute pancreatitis. Zhang et al from China69studied the TNF 308 
polymorphisms in 127 patients and 102 healthy controls with acute pancreatitis. They 
measured TNF alpha levels in all patients of acute pancreatitis at admission. Among the 61 
patients with severe pancreatitis in that study, TNF alpha levels at admission were similar in 
those patients who developed septic shock and those who did not. There was no significant 
correlation between the TNF alpha- 308 polymorphisms and plasma TNF alpha levels at 
admission in the patients studied. In 2008 de-Madaria et al studied TNF-238 polymorphisms, 
TNF alpha-308 polymorphisms and cytokine levels in patients with acute pancreatitis. In this 
study also, blood for genetic analysis and cytokine levels were collected at admission. Both 
the polymorphisms studied did not show any correlation with the cytokine levels in the 
patients studied. 
 
The studies on TNF levels, TNF gene polymorphism and severity of disease in acute  
pancreatitis have not shown any positive correlation with TNF levels and the severity of 
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illness. This could be because of numerous reasons. The blood sample for cytokine levels in 
all the studies is collected at admission. However different patients present at different times 
to the hospital after the onset of illness. Studies on experimental models of acute pancreatitis 
have shown that the concentration of TNF and IL-1 within pancreatic tissues was 
substantially higher than the  serum levels44. It might be that the tissue levels of TNF alpha 
are more important in the pathogenesis of acute pancreatitis than the serum levels.  The direct 
measurement of these cytokines in blood is often erratic in view of the intermittent nature of 
secretion, low half life of cytokines in circulation and clearance by the liver42. So if the 
disease severity can be positively correlated to a genetic polymorphism, that might serve as 
an excellent prognostic marker. 
 
TNF 308 G/A is the most widely studied polymorphism in the setting of acute pancreatitis. 
Our study did not show any association between TNF 308G/A polymorphisms and severity 
of disease in acute pancreatitis. Moreover the distribution of TNF genotypes did not satisfy 
the Hardy –Weinberg equilibrium. This was probably related to the absence of AA genotype 
in our study population. Of the 168 patients studied 160 had GG genotype and eight patients 
had GA genotype. Unpublished, population based data from our department had shown that 
the frequency of GA and AA genotypes in south Indian population is about eight percent. 
However the frequency in our study population was found to be different. The reason for this 
difference is not clear. 
 
In the study by Powell et al there were 190 patients with acute pancreatitis68. Of these 113 
patients had mild disease and 77 patients had severe disease.  The study did not show a 
positive correlation with TNF polymorphisms and the severity of disease. The study by 
Zhang et al from China69also did not show a positive correlation between TNF 308 G/A 
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polymorphisms and outcomes of acute pancreatitis. This study had a total of 127 patients, 
sixty one patients with severe pancreatitis and the rest with mild disease. This study however 
found a significant difference in the TNF alpha- 308 polymorphism distribution when 
comparing patients with and without septic shock.TNF2 was found in 50 % of patients who 
developed septic shock compared with 20.1 %of  patients with no septic shock (odds ratio- 
5.155, P=0.023). However in our study there was no association between TNF 308 G/A 
polymorphism with any of the systemic complications of pancreatitis, including hypotension. 
In a prospective single centre trial from Hungary, Balog A et al reported that the GA 
genotype was more common in patients with severe pancreatitis compared to those with mild 
disease with an odds ratio of 3.145. The number of homozygotes for the inflammatory allele 
(AA genotype) was very low in this study similar to our study(2 out of 77 patients). In one of 
the largest studies on TNF 308G/A polymorphisms in acute pancreatitis, Tukiainen 
etalstudied 397 patients with acute pancreatitis. The study failed to show any association 
between TNF 308 G/A polymorphisms and the outcomes and severity of acute pancreatitis. 
The study by de-Madaria et al published in 2008, also did not show any correlation between 
TNF genotypes and outcomes of acute pancreatitis. 
 
TNF 863 C/A polymorphism  and the outcomes of pancreatitis was studied by Bishehsariet al 
in the past. They found that the A allele was associated with an increased risk of progresssion 
to multiorgan dysfunction syndrome. However our study did not show any such association. 
Moreover the TNF 863 C/A polymorphism was not associated with any of the local 
complications or systemic complications of acute pancreatitis in our study. 
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Limitations of our study 
Being a tertiary referral centre, referral bias is an important limitation. Chronic pancreatitis 
was not excluded by imaging in all our patients. A CT scan was done only in eighty three 
patients  (49.4%) of the total study population. Due to the same reasons we could have 
missed a few local complications of acute pancreatitis. Our sample size calculation was based 
on the assumption that two thirds of the patients with acute pancreatitis will have mild acute 
pancreatitis and one third will have severe disease. However in our study population only 
43% had mild disease and 57% had severe disease. The distribution of TNF 308 G/A 
genotypes in our study population did not satisfy the Hardy –Weinberg equilibrium. 
 
The future implications 
If future studies also prove that the severity of disease and outcomes in acute pancreatitis 
show a positive correlation with TNF 857 C/T polymorphisms, this test can serve as an 
excellent prognostic marker and predictor of severity in patients with acute pancreatitis. This 
might help us to prioritize patients and plan early ICU admission in those who are likely to 
deteriorate. Unlike the cytokine levels which tend to vary with time, this test being a genetic 
test can be done at any time since the results do not change with time. 
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1. Alcohol was the commonest etiology of acute pancreatitis in our study population 
2. 82% of our patients were males 
3. 76.7% of our patients were in the age group 18-55 years 
4. 42.8% of the patients had a local complication 
5. Acute fluid collection was the commonest  local complication 
6. 14.2% of patients had a vascular complication secondary to acute pancreatitis 
7. 40.4% patients had a systemic complication of pancreatitis 
8. Acute lung injury was the commonest systemic complication 
9. Six patients had proven infected pancreatic necrosis 
10. 17.2% of patients had recurrent attacks of acute pancreatitis 
11. 43% of patients had mild acute pancreatitis while 57% of patients had severe acute 
pancreatitis 
12. 10.1% of our patients were admitted in the ICU 
13. The mortality in our study population was 8.9% 
14. The local complications, systemic complications and severity of illness in acute pancreatitis 
showed a positive correlation with TNF 857C/T polymorphism 
15. The other polymorphisms studied did not show any correlation with the outcomes of acute 
pancreatitis 
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 Informed Consent document &PATIENT’S INFORMATION 
 
I understand that Dr. JIFFY RASAK .V.A  is doing a study to identify the parameters   
that help in correlating the severity of acute pancreatitis and gene polymorphism.  The 
study involves being interviewed (about the disease) and noting the results of test reports 
that are being done by the treating doctors for clinical care. A sample of blood will be 
taken to find out if there is a particular kind of gene pattern that may predispose me (or 
my patient) to severe illness. The results of the test done in connection with the study may 
not directly benefit me.  They are likely to indirectly benefit other patients with the 
disease. 
 
I understand that my withdrawal from the study at any time will not affect the treatment 
being given. 
 
Study Title:     Study Number: 
Subject’s Initials: _________    Subject’s Name: ________ 
Date of Birth / Age:_______   Please initial box  
(Subject) 
 
(i) I confirm that I have read and understood the information sheet dated _________ for 
the above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal rights 
being affected. [ ] 
(iii) I understand that my identity will not be revealed in any information released to third 
parties or published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
(vi)I also give consent to use the blood samples for further  studies , provided such a use 
is only for scientific purpose and without disclosure of personal information. 
(vii) I understand that i can contact the investigator at 8220249723 at any time for further 
clarification regarding the study 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________  Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
                 
                                                      
 
                                               PROFORMA                              Study no. 
 
Demographic data 
Name  :       
Age (years) :  
Sex   : Male / Female      
Hosp Num :   
Occupation : 
Address : 
 
Phone No : 
 
Recruitment data 
  Outpatient follow-up  /  Emergency Service  /  Admitted to ward 
 
Clinical data 
Abdominal pain: Duration:  
   Location: Epigastrium  / Generalized  /  Other 
Precipitating factors: Alcohol binge  /  Fatty food  /  Trauma  /  Others  /  Nil 
Vomiting:  Yes  / No 
Breathlessness: Yes  /  No 
Decreased urine output: Yes  /  No 
GI bleed:  Yes  /  No 
Fever:   Yes  /  No 
Others:   
Alcohol consumption: Nil  /  Social  /  Alcoholic    Qty    Type      Yrs 
 
Admission characteristics: 
Pulse                    BP             Temp                 Respiratory rate 
 
Simplified Glasgow scoring system (Score >2 in first 48 h = severe) 
 
Variable  Absent  Present 
Age >55 yrs   
PaO2 <60 mm Hg   
WBC >15,000/mm3   
Ca2+ (uncorr.) <8 mg%   
LDH >600 IU/L   
Glucose >180 mg%   
Urea >45 mg%   
Albumin <3.2 g%   
TOTAL SCORE  
 
CRP  : 
S. Amylase  : 
S. Lipase  : 
PCV  : 
Chest X Ray:  Normal Y / N  (if abnormal, at admission or later?) 
   Effusion Y / N 
   ARDS  Y / N 
Ultrasonography:  
Gallstones / Biliary dilatation / Pancreatic oedema / Fluid collection / Other 
 
CECT:  Done / Not done  CTSI (if available: 
 
Findings: 
 
 
Hospital course:  
Admitted during study  /  Discharged from A&E  /  Date obtained from records  
(now seen in OPD) 
 
I) Local complication:    Acute fluid collection 
                                         Pseudocyst 
                                         Abscess   
 
II) Organ Failure:                  Yes   /   No 
CVS              Systolic BP <90 mm Hg 
Respiratory    PaO2 <60 mmHg 
Renal             Creatinine >2 mg/dl after rehydration 
Haematologic GI Bleed >500cc in 24 hours  
CNS  
Liver  
 
III) Sepsis: 
 
Hospital stay:       ____ days   DOA   DOD 
 
ICU stay:     No   /  Yes     If yes,    ____ days 
                    
Interventions:       
     Pressor support needed  N   /   Y  
      Ventilatory support needed  N   /   Y    (non-invasive / invasive) 
       Dialysis support needed  N   /   Y 
 
Feeding: TPN   /   NJ   /   Oral 
Surgery:     Yes   /   No 
Outcome: Dead    /   Alive 
 
Final Diagnosis: Acute pancreatitis (first attack) 
Aetiology : 
Severity : 
 
SL.NO HOSP. NO AGE SEX TNF 308 TNF 857 TNF 863 STATE OCCUPATION COMORBIDITIES PRESENTATION ADMISSION PAIN DURATION VOMITING BREATHLESSNESS OLIGURIA FEVER ALCHOHOLIC SGS SCORE SGS >2 CRP
1 846266D 30 1 GG CC CC 1 LABOURER 0 1 0 1 2 1 0 0 0 1 0 0 7.6
2 273703F 41 0 GG CT CA 2 HOUSE WIFE 0 1 1 1 3 1 0 1 0 0 5 1 168
3 287429F 39 1 GG CC CC 3 LABOURER 0 1 0 1 14 1 1 0 0 1 3 1 106
4 270969F 11 0 GG CC CC 4 STUDENT 0 1 1 1 3 1 0 0 0 0 0 0 6.6
5 265661D 51 1 GG CT CC 5 INSURANCE 0 1 1 1 10 1 0 0 0 1 1 0 92.7
6 291368F 31 1 GG CC CC 2 LABOURER 0 1 1 1 4 1 0 0 0 1 4 1 87
7 291698F 37 1 GG CC CC 1 BUSINESS 0 1 0 1 3 1 0 0 0 1 2 0 16
8 295458F 50 1 GG CC AA 5 PVT.JOB 1 2 1 1 45 1 1 0 0 0 4 1 8
9 452733B 16 1 GG CC CC 2 STUDENT 0 1 1 1 2 1 0 0 0 0 0 0 15
10 546009C 73 1 GG CT CC 2 RETIRED 1 1 1 1 1 1 0 0 0 0 3 1 33
11 194104F 43 1 GG CC CC 2 DRIVER 2 1 1 1 2 1 0 0 0 0 0 0 63
12 299207F 65 1 GG CC CC 2 RETIRED 3 1 1 1 2 1 0 0 0 0 3 1 88
13 475666A 28 1 GG CC CC 2 STUDENT 0 1 1 1 1 0 0 0 0 0 1 0 18
14 281093F 19 1 GG CT CA 5 STUDENT 0 1 1 1 2 1 0 0 0 0 0 0 16
15 261029F 32 1 GA CC CC 6 BUSINESS 0 2 1 1 60 0 1 0 0 1 3 1 91
16 730034C 63 1 GG CC CC 6 RETIRED 0 1 1 1 3 1 0 0 0 0 1 0 8
17 186660F 25 1 GG CC CA 5 LABOURER 0 1 1 1 3 1 0 0 0 0 0 0 16
18 313206F 29 1 GG CC CC 2 LABOURER 0 1 1 1 10 1 0 0 0 1 4 1 206
19 309557F 48 1 GG CC CC 1 PVT.JOB 0 1 1 1 4 1 0 0 0 1 6 1 174
20 309641F 29 1 GG CC CC 1 LABOURER 0 1 1 1 4 1 1 0 0 0 2 0 115
21 317233F 39 1 GG CT CC 2 BUSINESS 0 1 1 1 2 1 0 0 0 0 1 0 8.5
22 625181D 52 1 GG CT CC 4 BUSINESS 1 1 1 1 4 1 0 0 0 1 1 0 188
23 310081F 21 1 GG CC AA 5 STUDENT 0 1 1 1 2 1 0 0 0 0 0 0 34
24 338538F 32 1 GG CC CC 2 LABOURER 0 1 1 1 5 1 0 0 1 0 0 0 131
25 342730F 44 1 GG CC CC 5 HOUSE WIFE 0 1 1 1 5 1 0 0 0 0 1 0 6.9
26 316672F 29 1 GG CC CC 1 BUSINESS 0 2 1 1 30 1 1 0 1 1 6 1 181
27 331532F 61 1 GG CC CC 1 RETIRED 4 1 1 1 1 1 1 0 0 0 5 1 212
28 061735A 50 1 GG CC CC 2 CMC 4 1 1 1 1 1 0 0 0 1 1 0 17.1
29 341916F 42 1 GG TT CC 1 BUSINESS 1 1 1 1 2 1 0 0 0 1 0 0 137
30 350399F 34 1 GG CC CC 2 LABOURER 1 1 1 1 6 1 1 0 0 1 4 1 189
31 379724F 39 1 GG CT CC 1 PVT.JOB 2 1 0 1 3 1 1 0 0 0 3 1 115
32 475410C 58 1 GG CC CC 2 LABOURER 4 1 1 1 5 1 0 0 0 0 4 1 250
33 290269F 37 1 GG CC CC 2 MECHANIC 1 1 1 1 3 1 0 0 0 0 1 0 65.6
34 863110D 24 1 GG CC CC 2 LABOURER 0 1 1 1 5 1 1 0 1 1 3 1 204
35 374526F 36 1 GG CT CC 2 DRIVER 4 1 1 1 6 1 0 0 0 1 3 1 154
36 317925F 28 1 GG CC CC 2 SOCIAL WORKER 6 1 1 1 4 1 0 0 0 0 0 0 108
37 374333F 29 1 GG CC AA 1 LABOURER 0 1 1 1 4 1 1 0 1 1 5 1 206
38 367723F 59 0 GG CC AA 2 HOUSE WIFE 1 1 1 1 1 1 0 0 0 0 4 1 41
39 005245F 38 1 GG CC CC 1 SHOP KEEPER 0 1 1 1 2 1 0 0 0 1 0 0 51.3
40 373384A 65 1 GG CC CC 2 RETIRED 0 1 1 1 1 0 0 0 0 1 3 1 176
41 554522B 50 1 GG CT CA 2 LABOURER 1 1 1 1 3 1 0 0 0 1 3 1 204
42 315187F 49 1 GG CC CC 5 PVT.JOB 0 1 1 1 2 1 0 0 0 0 1 0 6
43 389154F 41 1 GG CT CA 1 ELECTRICIAN 0 1 1 1 5 1 1 0 0 1 3 1 204
44 379320F 33 0 GG CC AA 1 TEACHER 0 1 1 1 2 1 0 0 0 0 1 0 95
45 373239F 66 0 GG CC CC 2 HOUSE WIFE 4 1 1 1 3 1 0 0 0 0 1 0 12.4
46 361242F 40 1 GG CT CC 2 LABOURER 0 1 1 1 5 1 0 0 0 0 2 1 45
47 246773F 26 1 GG TT CC 2 PVT.JOB 0 1 1 1 2 1 0 0 0 1 0 0 114
48 309901F 23 1 GG CT CC 2 STUDENT 0 1 1 1 1 1 0 0 0 0 2 0 16.6
49 394317F 59 1 GG CC CC 1 RETIRED 3 1 1 1 2 1 0 0 0 1 1 0 106
50 674160C 78 1 GG CC CC 2 RETIRED 1 1 1 1 2 0 0 0 0 0 1 0 48.5
51 013331F 52 1 GG CC CC 1 HOUSE WIFE 7 1 1 1 2 1 0 0 0 0 2 0 76.2
52 401398F 66 1 GG CC CC 1 RETIRED 1 1 1 1 1 1 0 0 0 0 2 0 76.9
53 401469F 26 1 GG CC CC 1 FINANCIER 8 1 1 1 4 1 1 0 0 1 1 0 204
54 401388F 49 1 GG CC AA 2 ACCOUNTANT 3 1 1 1 5 0 0 0 0 0 2 0 204
55 379541F 21 1 GG CC CC 2 HOUSE WIFE 0 1 1 1 3 0 0 0 0 0 0 0 29
56 273445F 25 0 GG CC CC 2 HOUSE WIFE 0 1 1 1 2 0 0 0 0 0 1 0 143
57 337421F 33 1 GG CC CC 6 BUSINESS 0 2 1 1 36 0 0 0 0 1 3 1 204
58 396429F 43 1 GG CC CC 6 PVT.JOB 0 2 1 35 0 0 0 0 0 1 3 1 168
59 406258F 46 1 GG CC CC 1 BUSINESS 3 1 1 1 3 1 0 0 0 0 3 1 167
60 406386F 30 1 GG CC CC 2 LABOURER 0 1 1 1 1 1 0 0 0 1 2 1 70.5
61 422613F 28 1 GG CC AA 1 BUSINESS 0 1 1 1 2 1 1 0 0 1 4 1 204
62 566953D 64 1 GG CC CA 5 BUSINESS 9 1 1 1 3 1 0 0 0 0 2 0 167
63 426145F 41 1 GG CC AA 6 HOUSE WIFE 0 1 1 1 1 1 0 0 0 0 0 0 86
64 422515F 32 1 GG CT CC 2 MECHANIC 1 1 1 1 1 1 1 0 0 0 3 1 204
65 431386F 55 0 GG CC AA 5 HOUSE WIFE 10 1 1 1 15 1 0 0 0 0 1 0 11
66 434580F 61 1 GG CC CC 2 RETIRED 4 1 1 1 2 1 0 0 0 1 2 0 99.7
67 434625F 34 1 GG CC CC 1 PVT.JOB 0 1 1 1 4 1 0 0 0 1 1 0 12.8
68 434615F 31 1 GG CC CC 1 BUSINESS 0 1 1 1 2 1 1 1 0 1 3 1 206
69 441582F 35 1 GG CC CC 5 BUSINESS 0 1 1 1 3 0 0 0 1 1 3 1 76.7
70 448492F 71 1 GG CC AA 2 RETIRED 9 1 1 1 5 0 0 0 0 1 3 1 124
71 455700F 34 1 GG CC CA 1 BUSINESS 0 1 1 1 2 1 0 0 0 1 2 0 129
72 455371F 46 1 GG CC CA 1 LABOURER 0 1 1 1 5 1 1 0 0 1 5 1 206
73 455941F 35 1 GA CC CA 2 LABOURER 0 1 1 1 3 1 0 0 0 1 2 0 204
74 471690F 39 1 GG CC CA 5 BUSINESS 0 2 1 1 30 1 0 0 0 0 0 0 125
75 937754F 58 0 GG CT CC 2 HOUSE WIFE 1 1 1 1 4 1 0 0 0 0 3 1 60.5
76 474239F 35 1 GG CC CC 1 BUSINESS 0 1 1 1 10 1 0 0 0 1 2 1 204
77 458968F 21 1 GG CC CC 7 STUDENT 0 1 1 1 2 1 0 0 0 0 1 0 39.9
78 072576F 25 0 GG CC CC 2 HOUSE WIFE 0 1 1 1 3 1 0 0 0 0 0 0 5
79 473374F 28 1 GG CC CC 1 PVT.JOB 0 1 1 1 4 1 0 0 0 1 3 1 204
80 703980S 39 1 GG TT CC 2 PVT.JOB 1 1 1 1 2 1 0 0 0 1 2 0 67
81 476087F 51 0 GG CC CC 2 HOUSE WIFE 0 1 1 1 3 1 0 1 0 0 5 1 184
82 476410F 39 1 GG CC CC 2 LABOURER 0 1 1 1 4 1 0 0 0 1 5 1 204
83 485922F 36 1 GG CC CC 2 LABOURER 0 1 1 1 3 1 0 0 0 1 2 0 204
84 797188C 41 0 GG CC CC 2 HOUSE WIFE 0 1 1 1 5 0 0 0 0 0 0 0 78.8
85 396269B 17 1 GG CC CC 2 STUDENT 0 1 1 1 3 1 0 0 0 0 0 0 16
86 604499F 41 1 GA CC CC 1 COMPUTER OPERATER 0 1 1 1 3 1 0 0 0 0 0 0 188
87 612254F 35 1 GG CC CA 1 BUSINESS 3 1 1 1 20 1 0 0 0 1 0 0 44
88 620584D 31 1 GG CC CC 2 ARMY 0 1 1 1 3 1 0 0 0 1 2 0 204
89 490783F 43 1 GG CT CC 1 LABOURER 2 1 1 1 7 1 0 0 0 1 4 1 206
90 604965F 38 1 GG CC CC 2 FARMER 5 1 1 1 5 1 0 0 0 1 1 0 142
91 479777F 65 1 GG CC CA 8 HOUSE WIFE 5 1 1 1 1 1 0 0 0 0 1 0 78
92 582566D 23 1 GG CC CC 2 PVT.JOB 0 1 1 1 3 1 0 0 0 0 0 0 108
93 604570F 39 1 GG CT CA 2 BUSINESS 0 1 1 1 4 1 1 0 0 0 1 0 138
94 458975F 34 1 GG CC AA 2 LABOURER 0 2 1 1 30 0 0 0 0 1 1 0 59
95 611698F 23 1 GA CC CC 1 DRIVER 0 1 1 1 5 1 0 0 0 1 2 1 204
96 604983 58 0 GG CC CA 1 HOUSE WIFE 4 1 1 1 4 1 1 0 1 0 4 1 4.3
97 611660F 48 1 GG CC AA 2 PVT.JOB 8 1 1 1 2 1 1 0 0 0 4 1 34
98 623540F 36 1 GG CC CC 2 TEA SHOP 0 1 1 1 2 1 0 0 0 1 1 0 99
99 623505F 32 1 GG CT CC 2 LABOURER 0 1 1 1 4 1 0 0 1 1 2 1 204
100 415599F 32 1 GG CC CC 2 PVT.JOB 0 1 1 1 1 1 0 0 0 0 1 0 4.7
101 646551F 65 0 GG CC CA 2 HOUSE WIFE 1 1 1 1 3 1 0 0 0 0 2 0 168
102 789454C 31 0 GG CC AA 2 PVT.JOB 0 1 1 1 3 1 0 0 0 1 2 0 61
103 644169F 61 1 GG CC AA 5 RETIRED 3 1 1 1 8 1 0 0 0 0 2 0 104
104 639560F 35 1 GG CC CC 1 BUSINESS 0 2 1 1 3 1 1 0 0 0 3 1 204
105 341719F 46 1 GG CC CC 2 PVT.JOB 4 1 1 1 3 1 0 0 0 1 1 0 147
106 129335A 50 0 GG CC CC 2 HOUSE WIFE 4 1 1 1 1 1 0 0 1 0 1 0 167
107 623624F 47 0 GG CC CA 6 HOUSE WIFE 1 2 1 1 30 1 1 0 1 0 5 1 186
108 113085F 33 1 GA CC CA 2 LABOURER 0 1 1 1 3 1 0 0 0 1 2 0 204
109 651610F 38 0 GG CC CC 2 HOUSE WIFE 0 1 1 1 2 1 0 0 0 0 0 0 16
110 701361A 80 1 GG CC CA 2 RETIRED 9 1 1 1 2 1 0 0 0 0 4 1 197
111 651775F 27 1 GG CC CA 2 PVT.JOB 0 1 1 1 2 1 0 0 0 0 2 0 221
112 657780F 18 0 GG CT CA 1 STUDENT 0 1 1 1 2 1 0 0 0 0 1 0 11
113 657646F 33 1 GG CT CA 1 LABOURER 0 1 1 1 2 1 0 0 0 1 2 0 33
114 374690F 46 0 GG CC CC 8 HOUSE WIFE 3 1 1 1 1 1 1 0 0 0 3 1 221
115 657667F 80 1 GG CC AA 1 RETIRED 9 1 1 1 2 1 0 0 0 0 2 0 68
116 664561F 39 1 GG CC AA 1 BUSINESS 0 1 1 1 2 1 0 0 0 1 1 0 152
117 664773F 42 1 GG CC CC 1 BUSINESS 3 1 1 1 1 1 0 0 0 0 0 0 143
118 648456F 57 0 GG CC CC 2 HOUSE WIFE 1 1 1 1 4 1 0 0 0 0 3 1 221
119 664696F 81 1 GG CC AA 2 RETIRED 4 1 1 1 1 1 1 0 0 0 4 1 186
120 656335F 59 1 GG CC AA 5 RETIRED 3 2 1 1 50 0 0 0 1 0 2 0 26
121 671530F 26 1 GG CC CA 1 LABOURER 0 1 1 1 1 1 0 0 0 0 0 0 12
122 671549F 41 1 GG CC CC 2 MECHANIC 8 1 1 1 3 1 0 0 0 1 0 0 6
123 651467F 16 1 GG CC AA 6 STUDENT 0 2 1 1 60 1 0 0 0 0 0 0 16
124 671492F 33 1 GG CC CA 1 DRIVER 0 1 1 1 4 1 0 0 1 1 4 1 221
125 671445F 40 1 GG CC CC 1 BUSINESS 0 1 1 1 3 1 0 0 0 1 1 0 133
126 686767F 14 0 GG CC AA 2 STUDENT 0 1 1 1 4 1 0 0 0 0 0 0 3.4
127 671710F 54 0 GG CT CA 9 HOUSE WIFE 0 2 1 1 40 0 0 0 1 0 4 1 204
128 675380F 32 1 GG CT CA 1 LABOURER 0 1 1 1 4 1 0 0 1 1 2 0 86
129 682369F 27 1 GG CC CA 5 PVT.JOB 0 1 1 1 3 1 0 0 0 1 0 0 3.4
130 490309F 21 0 GG CT CC 2 HOUSE WIFE 0 1 1 1 4 1 0 0 0 0 1 0 68
131 682656F 35 1 GG CC CC 6 BUSINESS 0 2 1 1 100 1 0 0 0 1 0 0 79
132 683304F 54 1 GG CT CC 5 BUSINESS 0 2 0 1 40 1 1 0 0 1 3 1 111
133 675744F 12 0 GG CT CA 2 STUDENT 0 1 1 1 4 1 1 0 0 0 4 1 221
134 089408F 17 0 GG CC CC 2 STUDENT 0 1 1 1 2 1 0 0 1 0 0 0 3.4
135 688425F 45 0 GG CC AA 6 HOUSE WIFE 0 1 1 1 5 1 0 0 0 0 0 0 11.8
136 092121F 60 1 GG CC CA 5 BUSINESS 0 1 1 1 1 1 0 0 0 0 1 0 152
137 665492F 25 1 GG CC CC 6 BUSINESS 0 1 1 1 6 1 0 0 0 1 1 0 165
138 691534F 38 1 GG CC CA 6 PVT.JOB 0 1 1 1 1 0 0 0 0 0 1 0 34
139 139558D 26 1 GG CC CA 2 PVT.JOB 0 1 1 1 5 1 0 0 0 0 1 0 128
140 696359F 18 1 GA CC CA 5 STUDENT 0 1 1 1 10 1 0 0 0 0 0 0 3.2
141 696742F 34 1 GG CT CC 1 BUSINESS 0 1 1 1 6 1 1 0 0 1 3 1 221
142 650166F 39 1 GG CC AA 5 GOVT EMPLOYEE 11 1 1 1 3 1 0 0 0 0 1 0 28.9
143 696344F 32 1 GG CC CC 1 BUSINESS 0 1 1 1 3 1 0 0 0 1 1 0 30.5
144 632730F 50 1 GG CC CA 5 BUSINESS 0 1 1 1 1 1 0 0 0 0 2 0 21.4
145 696968F 58 1 GG CC AA 2 RETIRED 1 1 1 1 2 1 0 0 0 0 2 0 101
146 704207F 30 1 GG CT CA 1 BUSINESS 0 2 1 1 15 0 0 0 0 1 1 0 84.5
147 792196C 63 1 GG CC CA 5 RETIRED 9 1 1 1 2 1 1 0 0 0 3 1 3.4
148 718519C 68 1 GG CC CA 2 RETIRED 1 1 1 1 2 1 0 0 0 0 3 1 35.6
149 666608B 60 0 GG CC CA 2 HOUSE WIFE 0 1 1 1 3 1 0 0 0 0 3 1 16
150 713275F 54 1 GG CT CC 2 GOVT EMPLOYEE 4 1 1 1 3 1 1 0 0 1 5 1 173.4
151 434120F 63 1 GG CC CC 2 RETIRED 0 1 1 1 1 1 0 0 0 0 1 0 3.4
152 713124F 35 1 GG CC CC 2 PVT.JOB 0 1 1 1 2 1 0 0 0 1 0 0 134
153 045008C 38 0 GG CC CA 2 HOUSE WIFE 1 1 1 1 2 1 1 0 0 1 4 1 221
154 094919F 29 1 GG CC CC 1 PVT.JOB 0 1 1 1 2 1 0 0 0 0 2 0 190
155 426257F 41 1 GG CC CA 2 MECHANIC 3 1 1 1 10 1 0 0 0 1 4 1 197
156 071001F 43 0 GG CT CC 2 HOUSE WIFE 0 1 1 1 3 1 0 0 0 0 2 0 200
157 720583F 32 1 GG CC CC 2 GOVT EMPLOYEE 0 1 1 1 2 1 0 0 0 1 4 1 126
158 726540F 24 1 GG CT CC 2 FACTORY WORKER 0 2 1 1 30 1 0 0 0 1 1 0 75
159 720903F 62 1 GG CC CA 2 RETIRED 9 1 1 1 4 1 1 0 0 0 4 1 218
160 720819F 39 0 GG CC CA 5 HOUSE WIFE 0 1 1 1 3 1 0 0 0 0 0 0 161
161 720845F 35 1 GG CC CA 1 BUSINESS 0 1 1 1 4 1 1 0 0 1 2 0 221
162 720805F 54 1 GG CC CC 2 LABOURER 1 2 1 1 50 1 0 0 1 1 4 1 221
163 455329F 40 1 GG CT CC 2 LABOURER 4 1 1 1 4 1 0 0 0 1 3 1 116
164 726261F 33 1 GA CT CC 1 BUSINESS 0 1 1 1 7 1 1 0 0 0 4 1 194
165 323801F 24 1 GA CC CA 1 BUSINESS 0 1 1 1 4 1 0 0 0 1 0 0 5.8
166 726860F 57 1 GG CC CC 1 AGRICULTURE 9 1 1 1 3 1 1 0 0 0 4 1 78
167 726349F 43 1 GG CT CC 1 BUSINESS 3 1 1 1 7 1 1 0 1 1 3 1 221
168 740002F 24 1 GG CC CA 5 MECHANIC 0 1 1 1 4 1 0 0 0 1 0 0 4.6
AMYLASE LIPASE PCV CXR USG CT EFFUSSION ARDS GALL STONES IHBRD PANCREATIC EDEMA ACUTE FLUID COLLECTION NECROSIS NECROTIC COLLECTION PSEUDOCYST WOPN INFECTED NECROSIS CHOLANGITIS BACTEREMIA
601 1537 47 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1216 1616 30 1 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0
497 820 31 1 1 0 2 0 0 0 1 0 0 0 0 0 0 0 0
780 434 36 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
294 455 32 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
1040 2034 63 1 1 1 1 0 0 0 1 1 1 0 0 0 0 0 0
155 404 39 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
20 53 37 1 1 0 0 0 1 0 1 0 0 0 1 0 0 0 0
1450 1950 36 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1074 3740 37 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0
1010 1551 37 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
841 1206 36 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0
1827 6000 34 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
410 923 38 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
220 316 33 1 1 1 2 0 0 0 0 0 0 0 1 0 0 0 0
262 433 41 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1957 2697 44 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
473 2195 54 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
224 165 37 1 1 1 2 0 0 0 1 1 1 0 0 0 0 0 0
281 282 51 1 1 0 2 0 1 0 1 0 0 0 0 0 0 0 0
2577 4588 50 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0
477 755 55 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
660 960 34 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
2803 1350 46 1 1 1 0 0 1 1 0 0 0 0 0 0 0 1 0
3026 6910 33 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0
67 73 43 1 1 1 2 1 0 0 1 1 1 0 0 0 1 0 0
1089 2232 38 1 1 0 2 0 1 0 1 1 0 0 0 0 0 0 0
559 1565 43 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1892 2292 40 1 1 1 1 0 0 0 1 1 1 0 0 0 0 0 0
711 1207 56 1 1 1 2 0 0 0 1 1 1 0 0 0 0 0 0
497 1270 42 1 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0
205 133 54 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
432 1708 54 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
109 372 42 1 1 1 1 0 0 0 1 1 0 0 0 0 0 0 0
52 230 39 1 1 0 1 0 0 0 1 1 0 0 0 0 0 0 0
641 518 28 1 1 1 1 0 0 0 1 1 0 0 0 0 0 0 0
2824 3565 52 1 1 0 2 1 0 0 1 0 0 0 0 0 0 0 0
3148 9958 47 1 1 1 2 0 0 0 1 0 0 0 0 0 0 0 0
371 800 49 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
3772 7080 50 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
866 2050 60 1 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0
3440 1266 40 1 1 1 2 0 1 1 1 0 0 0 0 0 0 1 0
57 49 34 1 1 1 2 0 0 0 1 0 1 0 0 0 0 0 0
1579 1322 36.3 1 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0
531 2595 38 1 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0
271 1064 42 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
766 599 55 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1801 3600 32 1 1 1 1 0 0 0 1 1 1 1 0 0 0 0 0
2304 4160 46 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
2058 4091 40 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0
1500 2000 40.2 1 1 0 2 0 0 0 1 0 0 0 0 0 0 0 0
1133 1763 42.5 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
77 145 51 1 1 0 2 0 0 0 1 0 0 0 0 0 0 0 0
428 600 42 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0
2314 3456 33 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0
1908 8930 40 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0
225 68 33 1 1 1 0 0 0 0 1 0 0 0 1 0 0 0 0
1596 759 31 1 1 1 0 0 0 0 1 0 1 0 1 0 0 0 0
171 1027 46 1 1 1 0 0 1 0 1 1 0 0 0 0 0 0 0
748 1000 50 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
350 1950 55 1 1 1 2 0 0 0 1 1 0 0 0 0 0 0 0
185 385 43 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 1
2197 7402 34 1 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0
527 1008 49 1 1 1 2 0 0 0 1 1 1 0 0 0 0 0 0
709 3314 39 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0
1480 1200 40 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
403 668 45 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
271 400 47 1 1 1 1 0 0 0 1 1 1 0 0 0 0 0 1
298 477 27 1 1 1 1 0 0 0 1 1 1 0 0 0 0 0 0
1094 949 33 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
2053 4304 45 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0
867 955 44 1 1 0 0 1 0 0 1 1 0 0 0 0 0 0 0
902 1463 53 1 1 1 2 0 0 0 1 1 1 0 1 1 0 0 0
1659 4381 38 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 0
1924 4209 35 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
86 56 35 1 1 1 2 0 0 0 1 1 0 0 0 0 0 0 0
1715 3600 41 1 1 1 2 0 0 0 1 1 1 0 0 0 0 0 0
1730 4758 36 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0
534 920 42 1 1 1 1 0 0 0 1 1 0 0 0 0 0 0 0
921 1790 58 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
2987 2392 34 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 1
1789 2729 50 1 1 1 0 1 0 0 1 1 1 0 0 0 1 0 1
258 362 51 1 1 1 1 0 0 0 1 1 1 0 0 0 0 0 0
817 319 39 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1810 4616 48 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
285 705 41 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
71 83 41 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0
534 1217 54 1 1 1 2 0 0 0 1 1 1 0 1 0 0 0 0
1793 313 49 1 1 1 2 0 0 0 1 1 0 0 0 0 0 0 0
279 359 47 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
948 184 31 1 1 0 0 0 1 0 1 0 0 0 0 0 0 1 0
432 278 41 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0
1782 2347 44 1 1 1 0 0 1 1 1 1 1 0 0 0 0 0 0
288 589 38 1 1 1 0 0 0 0 1 1 1 1 1 0 0 0 0
164 181 53 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
624 3525 35 1 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0
750 2236 31 1 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0
381 834 45 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
454 591 36 1 1 1 2 0 0 0 1 0 1 0 1 1 1 0 0
1364 4636 45 1 1 1 0 0 0 1 1 0 0 0 0 0 0 1 0
213 167 37 1 1 1 1 0 0 0 1 1 0 0 0 0 0 0 0
383 989 52 1 1 1 2 0 0 0 1 0 0 0 0 0 0 0 0
280 1024 48 1 1 1 0 0 1 1 1 0 0 0 0 0 0 1 1
234 400 45 1 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0
300 870 44 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
325 1396 38 1 1 0 0 0 1 1 1 0 0 0 0 0 0 1 0
64 78 19 1 1 1 0 1 1 1 1 0 1 0 0 0 1 0 1
568 1034 51 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
230 487 37 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
1029 1680 36 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 0
566 1026 41 1 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0
1776 2707 35 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
467 1145 32 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
750 1822 26 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 1
332 232 37 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
292 749 51 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1273 1455 48 1 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0
119 216 38 1 1 1 2 0 0 0 1 1 1 0 0 0 0 0 0
2271 4460 36 1 1 1 2 0 0 0 1 1 0 0 0 0 0 0 0
106 83 38 1 1 1 0 0 0 1 1 0 0 0 1 0 0 1 1
633 1493 48 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
429 1231 52 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
198 69 38 1 1 1 1 0 0 0 1 1 1 0 1 0 0 0 0
230 161 37 1 1 1 1 0 0 0 1 1 0 0 0 0 0 0 0
283 810 36 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
108 193 36 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
96 27 21 1 1 1 2 0 1 0 1 0 1 0 0 0 1 0 0
315 111 38 1 1 0 2 0 0 0 1 1 0 0 0 0 0 0 0
227 32 47 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 0
2540 6480 44 1 1 0 0 0 0 1 1 1 0 0 0 0 0 0 0
129 651 39 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0
78 38 23 1 1 1 2 0 0 0 1 0 1 0 0 1 1 0 1
820 2198 41 1 1 0 2 0 1 0 1 1 0 0 0 0 0 0 0
3585 7684 33 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
124 176 34 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0
1450 1950 41 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
35 56 28 1 1 1 0 0 0 0 1 0 1 0 1 0 0 0 0
1286 1643 31 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1885 3183 41 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0
1999 4448 39 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
128 359 46 1 1 1 2 0 1 0 1 1 1 0 0 0 0 0 0
549 339 42 1 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0
1138 2380 45 1 1 1 1 0 0 0 1 1 0 0 0 0 0 0 0
771 2951 39 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1590 1754 46 1 1 0 0 0 1 1 1 0 0 0 0 0 0 1 0
90 90 42 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0
1038 5540 30 1 1 0 1 0 1 0 1 1 0 0 0 0 0 0 0
3981 20890 49 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0
1113 6290 44 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
1047 3680 55 1 1 1 1 0 0 0 1 1 1 0 0 0 0 0 0
741 1320 43 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
444 588 43 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
147 1003 43 1 1 1 3 0 0 0 1 1 1 0 0 0 0 0 0
711 1373 51 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0
62 105 40 1 1 1 1 0 0 0 1 1 0 0 0 0 0 0 1
1900 4560 39 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
520 878 62 1 1 1 2 0 0 0 1 0 1 0 0 0 0 0 0
681 289 39 1 0 1 1 0 0 0 1 0 1 0 0 1 0 0 0
5786 8146 48 1 1 0 2 0 1 0 1 1 0 0 0 0 0 0 0
1831 2070 38 1 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0
168 415 51 1 1 0 2 0 0 0 1 0 0 0 0 0 0 0 0
49 42 40 1 1 1 0 0 1 0 1 1 0 0 0 0 0 0 0
268 1100 36 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0
1324 1543 43 1 1 1 2 0 1 0 1 1 1 0 0 0 0 0 0
925 892 45 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0
1343 691 51 1 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0
14 14 36 1 1 1 2 0 0 0 1 0 1 0 0 0 0 0 1
266 257 42 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0
ORGANISM INFECTED COLLECTION ORGANISM ANTIBIOTIC USE PANCREATIC ASCITIS SV/PV /SMVTHROMBOSIS HYPOTENSION CREAT >1.9 ALI/ARDS HOSPITAL  STAY ICU ICU-DURATION INOTROPES VENTILATION
0 0 0 0 0 0 0 1 0 0 0
0 1 0 1 1 1 1 8 1 8 1 1
0 0 0 0 0 0 1 1 0 0 0
0 0 0 0 0 0 0 5 0 0 0
0 0 0 0 0 0 0 6 0 0 0
0 1 0 0 0 0 0 20 0 0 0
0 0 0 0 0 0 0 1 0 0 0
0 0 0 0 0 0 0 16 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 0 0 0 0 0 0 8 0 0 0
0 0 0 0 0 0 0 6 0 0 0
0 1 0 0 1 0 1 4 0 1 1
0 1 0 0 0 0 0 8 0 0 0
0 0 0 0 0 0 0 6 0 0 0
0 1 1 0 1 0 0 42 0 1 0
0 0 0 0 0 0 0 2 0 0 0
0 0 0 0 0 0 0 8 0 0 0
0 0 0 0 1 1 1 1 1 1 1 1
0 1 0 1 0 0 1 11 0 0 0
0 0 0 0 0 0 1 12 0 0 0
0 0 0 0 0 0 0 10 0 0 0
0 0 0 0 0 0 0 5 0 0 0
0 0 0 0 0 0 0 8 0 0 0
0 1 0 0 0 0 0 5 0 0 0
0 1 0 0 0 0 0 9 0 0 0
1 ENTEROCOCCUS,ECOLI, PSEUDOMONAS 1 0 0 1 0 1 37 1 36 1 1
1 ENTEROBACTER 1 1 0 1 1 1 7 1 7 1 1
0 0 0 0 0 0 0 4 0 0 0
0 1 0 0 0 0 0 16 0 0 0
0 1 0 3 0 0 1 13 0 0 0
0 0 0 0 0 1 1 0 0 0
0 0 0 0 1 0 1 6 1 5 1 1
0 0 0 0 0 0 0 9 0 0 0
0 0 0 0 0 0 1 7 0 0 0
0 0 0 0 0 0 1 4 0 0 0
0 1 0 0 0 0 0 14 0 0 0
0 0 0 0 1 1 1 1 1 1 1 1
0 0 0 1 0 0 1 11 0 0 0
0 0 0 0 0 0 0 5 0 0 0
0 0 0 0 0 0 0 5 0 0 0
0 0 0 0 0 0 1 7 0 0 0
0 1 0 0 0 0 0 11 0 0 0
0 1 0 1 0 0 1 7 0 0 0
0 0 0 0 0 0 0 5 0 0 0
0 0 0 0 0 0 0 8 0 0 0
0 0 0 0 0 0 0 3 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 0 0 1 0 0 1 17 1 5 0 1
0 0 0 0 0 0 0 9 0 0 0
0 0 0 0 0 0 0 9 0 0 0
0 0 0 0 0 0 1 5 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 1 0 0 0 0 1 21 0 0 0
0 0 0 0 0 0 0 6 0 0 0
0 0 0 0 0 0 0 8 0 0 0
0 0 0 0 0 0 0 5 0 0 0
0 1 0 0 0 0 0 14 0 0 0
0 0 0 1 0 0 0 18 0 0 0
0 1 0 0 0 0 0 11 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 1 1 0 0 0 1 20 1 14 0 1
KLEBSIELLA 0 1 0 0 0 0 0 7 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 1 0 0 0 0 1 15 0 0 0
0 0 0 0 0 0 0 6 0 0 0
0 0 0 0 0 0 1 12 0 0 0
0 0 0 0 0 0 0 3 0 0 0
ENTEROCOCCUS 0 1 1 2 1 1 1 8 1 8 1 1
0 1 0 1 0 0 0 11 0 0 0
0 0 0 0 0 0 0 7 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 1 0 0 0 1 1 8 1 7 0 1
0 1 0 2 0 0 1 33 0 0 0
0 0 0 0 0 0 0 9 0 0 0
0 0 0 0 0 0 1 8 0 0 0
0 1 0 0 0 0 0 7 0 0 0
0 1 0 0 0 0 0 13 0 0 0
0 0 0 0 0 0 0 2 0 0 0
0 1 0 0 0 0 1 11 0 0 0
0 0 0 0 0 0 0 4 0 0 0
E.COLI 0 1 0 0 0 1 1 8 0 0 0
SALMONELLA 1 KLEBSIELLA,ENTEROBACTER 1 0 0 0 1 1 33 1 27 0 1
0 1 0 0 0 0 0 10 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 0 0 0 0 0 0 2 0 0 0
0 0 0 0 0 0 0 3 0 0 0
0 0 0 0 0 0 0 12 0 0 0
0 0 0 1 0 0 0 11 0 0 0
0 1 1 3 0 0 1 32 1 8 0 0
0 0 0 0 0 0 0 4 0 0 0
0 1 0 0 0 0 1 21 0 0 0
0 0 0 0 0 0 0 3 0 0 0
0 0 0 0 0 0 1 13 0 0 0
0 0 1 0 0 0 1 7 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 1 0 0 1 0 0 8 0 1 0
0 1 0 0 1 1 1 7 1 1 1 1
0 0 0 0 0 0 0 5 0 0 0
0 1 0 1 0 1 0 14 0 0 0
0 1 0 0 0 0 0 11 0 0 0
0 0 0 0 0 0 1 8 0 0 0
0 0 0 0 0 0 1 7 0 0 0
0 1 0 0 0 0 0 10 0 0 0
0 1 0 0 1 1 1 23 1 23 1 1
0 0 0 0 0 0 1 3 0 0 0
0 1 0 0 0 0 0 5 0 0 0
ENTEROBACTER 1 KLEBSIELLA, E.COLI 1 0 4 1 0 1 58 1 46 1 1
0 0 0 0 0 0 1 8 0 0 0
0 0 0 0 0 0 0 5 0 0 0
0 1 0 0 0 0 1 14 0 0 0
0 0 0 0 0 0 1 8 0 0 0
0 0 0 0 0 0 0 5 0 0 0
0 0 0 0 0 0 1 7 1 3 0 0
E.COLI 0 1 0 0 0 0 1 16 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 0 0 0 0 0 0 6 0 0 0
0 1 0 0 0 0 1 16 0 0 0
0 0 0 1 0 0 1 8 0 0 0
E.COLI 0 1 0 0 0 0 0 16 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 0 0 0 0 0 0 3 0 0 0
0 0 0 0 0 0 1 30 0 0 0
0 1 0 0 0 0 1 17 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 0 0 0 0 0 0 4 0 0 0
1 E.COLI 1 0 0 0 0 1 44 0 0 0
0 0 0 0 0 0 0 9 0 0 0
0 0 0 1 0 0 0 4 0 0 0
0 0 0 0 0 0 0 9 0 0 0
0 1 0 0 0 0 0 30 0 0 0
0 1 0 1 0 0 0 40 1 20 0 0
0 0 0 0 0 0 1 8 0 0 0
0 1 0 0 0 0 0 7 0 0 0
0 0 0 0 0 0 0 13 0 0 0
0 0 0 0 0 0 0 7 0 0 0
0 0 0 1 0 0 0 8 0 0 0
0 0 0 0 0 0 0 8 0 0 0
0 0 0 0 0 0 0 6 0 0 0
0 0 0 0 0 0 0 10 0 0 0
1 E.COLI 1 0 1 0 0 1 30 0 0 0
0 1 0 0 0 0 0 8 0 0 0
0 0 0 0 0 0 0 8 0 0 0
0 0 0 0 0 0 0 7 0 0 0
0 1 0 0 0 0 0 7 0 0 0
0 0 0 1 0 0 0 12 0 0 0
0 0 0 0 0 0 1 12 0 0 0
0 0 0 0 0 0 0 6 0 0 0
0 0 0 0 0 0 0 7 0 0 0
0 1 0 1 0 0 1 18 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 0 0 0 0 0 1 8 0 0 0
0 0 0 0 0 0 0 4 0 0 0
STAPH.AUREUS 0 1 0 0 0 0 1 16 0 0 0
0 0 0 0 0 0 0 7 0 0 0
0 0 0 1 0 0 1 7 0 0 0
0 0 0 0 0 0 0 6 0 0 0
0 0 0 0 0 0 1 14 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 0 0 0 0 0 1 8 0 0 0
0 1 0 0 0 0 1 20 0 0 0
0 0 0 0 0 0 0 3 0 0 0
0 1 0 1 0 0 1 11 0 0 0
0 0 0 0 0 0 0 4 0 0 0
0 0 0 0 0 0 0 5 0 0 0
BURKHOLDERIA 0 1 0 1 0 0 1 12 0 0 0
0 0 0 0 0 0 0 5 0 0 0
DIALYSIS LOCAL COMPLICATION SYSTEMIC COMPLICATION TRANSIENT/PERSISTANT GI BLEED FEEDING SURGERY DEATH/DAMA ETIOLOGY RECURRENT SEVERITY
0 0 0 0 2 0 0 ALCHOHOL 1 1
1 0 1 2 0 3 0 1 GALLSTONE,  HYPERCALCEMIA 0 3
0 0 1 2 0 1 0 0 ALCHOHOL 0 3
0 0 0 0 2 0 0 IDIOPATHIC 1 1
0 0 0 0 3 0 0 ALCHOHOL 0 1
0 1 0 0 3 0 0 ALCHOHOL 0 2
0 0 0 0 2 0 0 ALCHOHOL 0 1
0 1 0 0 2 0 0 GALLSTONE 0 2
0 0 0 0 2 0 0 IDIOPATHIC 1 1
0 1 0 0 2 0 0 IDIOPATHIC 0 2
0 0 0 0 2 0 0 ART INDUCECD 0 1
0 1 1 2 0 1 0 1 IDIOPATHIC 0 3
0 0 0 0 2 0 0 POST ERCP 0 1
0 0 0 0 2 0 0 IDIOPATHIC 1 1
0 1 1 2 0 3 0 0 ALCHOHOL 0 3
0 0 0 0 2 0 0 IDIOPATHIC 1 1
0 0 0 0 2 0 0 ANATOMIC ABNORMALITY 1 1
0 0 1 2 0 1 0 1 ALCHOHOL 0 3
0 1 1 2 0 3 0 0 ALCHOHOL 0 3
0 0 1 1 0 3 0 0 HYPERPARATHYROIDISM 0 2
0 0 0 0 2 0 0 GALLSTONE 0 1
0 0 0 0 2 0 0 ALCHOHOL 0 1
0 0 0 0 3 0 0 HYPERPARATHYROIDISM 1 1
0 0 0 0 2 0 0 GALLSTONE 0 1
0 0 0 0 2 0 0 GALLSTONE 0 1
0 1 1 2 1 3 1 2 ALCHOHOL 0 3
0 1 1 2 0 1 0 1 GALLSTONE 0 3
0 0 0 0 2 0 0 ALCHOHOL 0 1
0 1 0 0 3 0 0 ALCHOHOL 0 2
0 1 1 2 1 3 0 0 ALCHOHOL 0 3
0 0 1 2 0 1 0 0 ART INDUCECD 0 3
0 0 1 2 0 1 0 1 IDIOPATHIC 0 3
0 0 0 0 3 0 0 ALCHOHOL 1 1
0 1 1 1 0 2 0 0 ALCHOHOL 0 2
0 1 1 1 0 2 0 0 ALCHOHOL 0 2
0 1 0 0 2 0 0 CHEMOTHERAPY 0 2
0 0 1 2 0 1 0 1 ALCHOHOL 0 3
0 1 1 1 0 2 0 0 IDIOPATHIC 0 2
0 0 0 0 2 0 0 ALCHOHOL 1 1
0 0 0 0 2 0 0 ALCHOHOL 1 1
0 1 1 1 0 1 0 0 ALCHOHOL 1 2
0 0 0 0 2 0 0 GALLSTONE 0 1
0 1 1 1 0 2 0 0 ALCHOHOL 1 2
0 0 0 0 2 0 0 HYPERPARATHYROIDISM 0 1
0 0 0 0 2 0 0 GALLSTONE 0 1
0 0 0 0 2 0 0 ALCHOHOL 0 1
0 0 0 0 2 0 0 ALCHOHOL 1 1
0 1 1 2 0 3 0 0 IDIOPATHIC 0 3
0 0 0 0 3 0 0 ALCHOHOL 0 1
0 0 0 0 2 0 0 GALLSTONE 0 1
0 0 1 1 0 2 0 0 IDIOPATHIC 1 2
0 0 0 0 2 0 0 IDIOPATHIC 0 1
0 0 1 2 0 2 0 0 ALCHOHOL 0 3
0 0 0 0 2 0 0 GALLSTONE 0 1
0 0 0 0 2 0 0 GALLSTONE 0 1
0 0 0 0 2 0 0 GALLSTONE 0 1
0 1 0 0 2 2 0 ALCHOHOL 0 2
0 1 0 0 3 0 0 ALCHOHOL 0 2
0 1 0 0 3 0 0 GALLSTONE 0 2
0 0 0 0 2 0 0 ALCHOHOL 0 1
0 1 1 2 0 3 0 0 ALCHOHOL 0 3
0 0 0 0 2 0 0 GALLSTONE 0 1
0 0 0 0 2 0 0 GALLSTONE 1 1
0 1 1 2 0 3 0 2 ALCHOHOL 0 3
0 0 0 0 2 0 0 GALLSTONE 0 1
0 0 1 2 0 3 0 0 ALCHOHOL 0 3
0 0 0 0 2 0 0 ALCHOHOL 0 1
0 1 1 2 0 3 0 1 ALCHOHOL 0 3
0 1 0 0 3 0 0 ALCHOHOL 0 2
0 0 0 0 3 0 0 ALCHOHOL 0 1
0 1 0 0 2 0 0 ALCHOHOL 0 2
1 1 1 2 0 3 0 2 ALCHOHOL 0 3
0 1 1 2 0 3 0 0 ALCHOHOL 1 3
0 1 0 0 3 0 0 IDIOPATHIC 0 2
0 0 1 1 0 2 0 0 IDIOPATHIC 0 2
0 1 0 0 3 0 0 ALCHOHOL 1 2
0 1 0 0 3 0 0 IDIOPATHIC 1 2
0 0 0 0 2 0 0 GALLSTONE 0 1
0 1 1 2 0 3 0 0 ALCHOHOL 1 3
0 0 0 0 2 0 0 ALCHOHOL 0 1
0 0 1 2 0 2 0 0 IDIOPATHIC 0 3
1 1 1 2 0 3 0 1 ALCHOHOL 0 3
0 1 0 0 2 0 0 ALCHOHOL 0 2
0 0 0 0 2 0 0 IDIOPATHIC 0 1
0 0 0 0 2 0 0 IDIOPATHIC 1 1
0 0 0 0 2 0 0 IDIOPATHIC 0 1
0 1 0 0 3 0 0 ALCHOHOL 0 2
0 1 0 0 3 1 0 ALCHOHOL 1 2
0 1 1 2 0 3 0 0 ALCHOHOL 0 3
0 0 0 0 2 0 0 ALCHOHOL 0 1
0 0 1 2 0 3 0 0 GALLSTONE 0 2
0 0 0 0 2 0 0 GALLSTONE 0 1
0 1 1 2 0 2 0 0 GALLSTONE 0 3
0 1 1 1 0 3 0 0 GALLSTONE 0 2
0 0 0 0 3 0 0 ALCHOHOL 0 1
0 0 1 2 0 0 0 0 IDIOPATHIC 0 3
0 0 1 2 0 3 0 1 LAMIVUDINE 0 3
0 0 0 0 2 0 0 ALCHOHOL 0 1
0 1 1 2 0 3 0 2 ALCHOHOL 0 3
0 0 0 0 2 0 0 IDIOPATHIC 1 1
0 1 1 1 0 2 0 0 IDIOPATHIC 0 2
0 0 1 1 0 2 0 0 ALCHOHOL 0 2
0 0 1 0 2 0 0 GALLSTONE 0 1
0 0 1 2 0 3 0 1 ALCHOHOL 0 3
0 0 1 1 0 2 0 0 ALCHOHOL 0 2
0 0 0 0 2 0 0 GALLSTONE 0 1
0 1 1 2 1 3 1 0 GALLSTONE 0 3
0 0 1 1 0 3 0 0 ALCHOHOL 0 2
0 0 0 0 2 0 0 IDIOPATHIC 0 1
0 1 1 2 0 2 0 0 IDIOPATHIC 0 3
0 0 1 1 0 2 0 0 IDIOPATHIC 0 1
0 0 0 0 2 0 0 IDIOPATHIC 0 1
0 0 1 2 0 2 0 0 ALCHOHOL 0 3
0 0 1 2 0 3 0 0 POST ERCP 0 3
0 0 0 0 2 0 0 IDIOPATHIC 0 1
0 0 0 0 2 0 0 ALCHOHOL 0 1
0 0 0 0 2 0 0 AMPULLARY GROWTH 0 1
0 1 1 2 0 3 0 0 IDIOPATHIC 0 3
0 1 1 1 0 3 0 0 IDIOPATHIC 0 2
0 1 0 0 0 0 0 IDIOPATHIC 0 2
0 0 0 0 3 0 0 IDIOPATHIC 0 1
0 0 0 0 2 0 0 ALCHOHOL 0 1
0 1 1 2 0 3 0 0 IDIOPATHIC 0 3
0 1 1 1 0 3 0 0 ALCHOHOL 0 2
0 0 0 0 2 0 0 ALCHOHOL 0 1
0 0 0 0 2 0 0 IDIOPATHIC 0 1
0 1 1 2 0 3 0 0 GALLSTONES 0 3
0 1 0 0 3 0 0 ALCHOHOL 1 2
0 1 0 0 3 0 0 ALCHOHOL 1 2
0 1 0 0 3 0 0 IDIOPATHIC 0 2
0 1 0 0 3 0 0 ALCHOHOL 0 2
0 1 1 2 0 3 0 2 ALCHOHOL 0 3
0 1 1 1 0 2 0 0 IDIOPATHIC 0 2
0 0 0 0 2 0 0 IDIOPATHIC 1 1
0 0 0 0 2 0 0 HYPERPARATHYROIDISM,GALLSTONES 0 1
0 0 0 0 2 0 0 IDIOPATHIC 0 1
0 1 0 0 3 0 0 ALCHOHOL 0 2
0 0 0 0 2 0 0 POST ERCP 0 1
0 1 0 0 2 0 0 IDIOPATHIC 1 2
0 0 0 0 2 0 0 HEPATITIS B 0 1
0 1 1 2 0 3 0 0 ALCHOHOL, GALL STONES 0 3
0 1 0 0 3 0 0 DRUG INDUCED 0 2
0 1 0 0 2 0 0 ALCHOHOL 0 2
0 0 0 0 2 0 0 POST ERCP 0 1
0 0 0 0 2 0 0 GALL STONE 0 1
0 1 0 0 2 0 0 ALCHOHOL 0 2
0 1 1 1 0 2 0 0 GALL STONE 0 2
0 0 0 0 3 0 0 GALL STONE 0 1
0 0 0 0 2 0 0 DRUG INDUCED 0 1
0 1 1 2 0 3 0 0 ALCHOHOL 0 3
0 0 0 0 2 0 0 IDIOPATHIC 0 1
0 0 0 0 2 0 0 ALCHOHOL 0 1
0 1 1 1 0 3 0 0 IDIOPATHIC 0 2
0 0 0 0 2 0 0 IDIOPATHIC 1 1
0 1 1 2 0 3 0 0 ALCOHOL 0 3
0 0 0 0 2 0 0 IDIOPATHIC 0 1
0 1 1 1 0 2 0 0 ALCOHOL 0 2
0 1 0 0 2 0 0 ALCOHOL 0 2
0 1 1 2 0 3 0 0 GALL STONE 0 3
0 0 0 0 2 0 0 GALL STONE 1 1
0 0 1 1 0 2 0 0 ALCOHOL 0 2
0 1 1 2 0 3 0 0 ALCOHOL,GALL STONE 0 3
0 1 0 0 2 0 0 ALCOHOL 0 2
0 1 1 2 0 3 0 0 GALL STONE 0 3
0 1 0 0 2 0 0 ALCOHOL 0 2
0 0 1 1 0 2 0 0 IDIOPATHIC 0 2
0 1 1 2 0 3 0 0 ALCOHOL 0 3
0 0 0 0 2 0 0 ALCOHOL 1 1
STATE- 1-AP 2-TAMIL NADU 3- BIHAR 4-KARNATAKA 5- WEST BENGAL 6-JHARKHAND 7-UP 8-TRIPURA 9-SIKKIM
PRESENTATION 1=ACUTE EPISODE 2-COMPLICATION
EFFUION 0-NIL 1-LEFT SIDED 2-BILATERAL
SV/PVTHROMBOSIS 0-NIL 1-SPLENIC VEIN 2-PORTAL VEIN 3-SMV 4-JEJUNAL ARTERY ANEURYSM
TRANSIENT/PERSISTANT 1-TRANSIENT 2-PERSISTANT
SEVERITY 1- MILD 2-MODERATE 3-SEVERE
DEATH/DAMA 0-ALIVE 1-DEATH 2-DAMA
COMORBIDITIES 1-HTN 2-RETRO VIRAL DISEASE 3-DM 4-DM&HTN 5-  IHD 6- AML 7-DM, HTN, ASTHMA 8- CHRONIC HEP B 9-ASTHMA/COPD 10- HYPOTHYROID  11-CA STOMACH
FEEDING 1-IV FLUIDS 2-ORAL 3- NJ 4-TPN
SURGERY 0- NO 1-0PEN 2-ENDOSCOPIC DRAINAGE
SGS SCORE 0-9
PANCREATIC EDEMA 0- NO 1-YES
ACUTE FLUID COLLECTION 0-N0 1-YES
NECROSIS 0-NO 1-YES
NECROTIC COLLECTION 0=NO 1-YES
PSEUDOCYST 0-NO 1-YES
WOPN 0-N0 1-YES
INFECTED NECROSIS 0-N0 1-YES
LOCAL COMPLICATION 0-NO 1-YES
SYSTEMIC COMPLICATION 0-NO 1-YES
ICU STAY 0- NO 1-YES
RECURRENT 0- FIRST EPISODE 1- RECURRENT ATTACK
